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Cellular transformation, the transition of normal cells into morphologically and functionally 
altered neoplastic cells, may be caused by a great variety of genetic and epigenetic alterations 
and ensuing aberrations in cellular signaling. Here, we focused on studying the transforming 
mechanisms of fibroblasts, and searched for possible common denominators in oncogenic 
signaling. 
 
The enzyme ornithine decarboxylase (ODC), which is the key regulator of the biosynthesis of 
polyamines, and essential for cell proliferation, has often been associated with neoplastic 
transformation. In normal cells ODC activity is strictly controlled, i.e. transiently increased in 
response to various growth stimuli, but becomes constitutively activated during cell 
transformation induced by carcinogens, viruses or oncogenes. The exact function of ODC in 
cell transformation has remained enigmatic. To test if ODC could be transforming by itself and 
potentially a common mediator of cell transformation, rodent fibroblasts were engineered to 
overexpress ODC in sense and antisense orientations. The constitutive overexpression of ODC 
induced full morphological transformation, increased cell proliferation and enabled 
anchorage-independent growth. The expression of ODC antisense or blocking the ODC activity 
with a specific inhibitor in cells transformed by v-src, in turn resulted in reversion of the 
transformed phenotype. These results indicate that ODC is both necessary and sufficient for 
cellular transformation of immortalized rodent fibroblasts and that oncogenes, such as v-src 
may, at least in part, exert their effects via ODC. 
 
We compared signal transduction components induced by platelet derived growth factor 
(PDGF) in cells transformed by different oncogenes and ODC, for possible common points of 
convergence. Src, the first and best studied oncogene, and Ras, the oncogene frequently 
mutated in human cancers were used as representatives of broad-spectrum oncogenic 
transformation. By comparing v-src and c-Ha-rasVal12 transformed cells to ODC-induced cell 
transformation and to their normal counterparts we were able to exclude several signal 
transduction molecules, reported earlier to be activated in a transformation-specific manner. 
Instead, all transformed cell lines were found to display a constitutive increase in the 
phosphorylation of c-Jun on its transactivation domain.  
 
Finally, the second key enzyme of polyamine biosynthesis, S-Adenosylmethionine 
decarboxylase was examined for its potential role in cell transformation. We showed that 
AdoMetDC overexpression surprisingly induces transformation both in sense and antisense 
conformations in rodent fibroblasts, and is highly tumorigenic in nude mice. AdoMetDC-
induced transformation culminated in c-Jun phosphorylation on its transactivation domain, 
likewise to v-src-, ras- and ODC-transformed cells. Dominant negative mutants of MEK1 and 
JNK1 as well as the Jun mutant TAM67 (the transactivation domain deleted) reverted the 
transformed phenotype and TAM67 further effectively inhibited the anchorage-independent 
growth of the AdoMetDC-transformed cells.  
AdoMetDC-transformed cells showed extremely aggressive growth in nude mice and the 
resulting tumors were characterized by chaotic neovascularization of a type of mosaicism in 
the tumor vessels. AdoMetDC-transformed cells were also very invasive in vitro and were 
shown to stimulate endothelial cell migration in 3D-matrigel assay. Angiogenic switch was 
triggered by an increase in VEGF expression and downregulation of thrombospondin-1 (TSP-
1). The reintroduction of TSP-1 into AdoMetDC-transformed cells resulted in reduction of cell 
proliferation and ability to grow in soft agar. Extracellular matrix degradation and invasive 
capacity required for invasion and metastasis was associated with induction of matrix 
metalloproteinase-2 (MMP-2) and larger isoforms of Tenascin-C.  
In conclusion, our studies on polyamine biosynthetic enzymes in cell transformation of rodent 
fibroblasts suggest an important role for ODC and AdoMetDC. Of specific interest, the 
AdoMetDC-transformed cells displayed very high invasiveness and chaotic angiogenesis in 
nude mice. Further, we identified several molecules potentially responsible for the 
angiogenic switch. By comparing the PDGF-induced signal transduction pathway of the 
ODC- and AdoMetDC-transformed cells to oncogenic Ras- and v-Src-transformed cells, we 
could identify c-Jun activation as a common point of convergence. Our findings are of 
interest not only for the field of polyamine research, but also generally for the dissection of 
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INTRODUCTION 
The polyamines putrescine, spermidine and spermine are involved in many fundamental 
processes of cell growth and survival, including association with nucleic acids, stabilization of 
chromatin structure, regulation of specific gene expression, differentiation, apoptosis, 
regulation of multiple ion-channels necessary for cell-to-cell communication and protection 
from oxidative damage and nucleic acid depurination [1-3]. Polyamines are indispensable for 
normal cell growth and their depletion results in cytostasis, a process by which cells stop 
dividing without dying [3, 4]. In contrast, when cells are stimulated to grow, polyamine 
synthesis is rapidly increased. The components of the polyamine biosynthetic pathway are 
highly conserved throughout evolution and the route harbors multiple tightly controlled steps 
in order to maintain a strict regulation of the polyamine levels [5, 6]. Even though dysregulated 
polyamine metabolism has frequently been associated with uncontrolled growth and cancer 
[7], evidence to indicate that polyamines have a contributing rather than an associative role 
in cancer has been lacking. 
The first and rate-limiting step in polyamine biosynthesis, the production of putrescine, is 
catalyzed by ornithine decarboxylase (ODC). All tissues studied so far have demonstrated the 
requirement for ODC activity in cell proliferation. The ODC activity is strictly controlled in 
normal cells, but becomes transiently upregulated upon growth factor stimulation [8-10]. ODC 
activity is constitutive during cell transformation induced by carcinogens [11, 12], viruses [13, 
14] or oncogenes [15-17].
The second important step in polyamine biosynthesis, the production of aminopropyl donor 
for the synthesis of higher polyamines spermidine and spermine is catalyzed by S-
adenosylmethionine decarboxylase (AdoMetDC) [8, 18, 19]. Similar to ODC, it has a fast 
turnover rate and is rapidly induced in various normal and neoplastic growth processes [20, 
21]. Inhibition of AdoMetDC by various drugs have been shown to have antiproliferative and 
antitumor activity and to inhibit metastasis [22-24]. However, direct evidence for the role of 
AdoMetDC in cell transformation has been missing. 
Compelling data has indicated that the polyamine pathway is a downstream target for known 
oncogenes and that inhibition of polyamine synthesis disrupts the action of these genes [1]. 
This has led to revival in the interest of targeting polyamine metabolism as an anticancer 
strategy [3]. Understanding the molecular functions of polyamines and the role of their 
biosynthetic enzymes in cancerous growth would be essential in achieving these goals.  
Transmission of the proliferative extracellular signals, like growth factor receptor activation 
by their ligands is mediated through the cytoplasm by cascades of activated cytoplasmic 
signaling molecules that ultimately lead to phosphorylation of transcription factors and to 
concomitant adaptation to the incoming signal [25]. Proliferation in normal cells is tightly 
regulated. Transformed cells, however, have escaped this control and can proliferate 
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independently from incoming signals [26]. One could reason that a transformed cell should 
display constitutive or improper activation of one or more components in the signaling 
pathways to gain independence of the growth regulation. Indeed, many of the molecules 
involved in various signal transduction pathways have been shown to be transforming in 
different cell lines. By comparing signal transduction pathways induced by the same activating 
growth factor, but in different oncogenic models, we searched for these possible points of 
convergence. These kinds of common relay points could have far-reaching importance, 
especially when designing new chemoprevention. 
3 
REVIEW OF THE LITERATURE 
1. Polyamines and their biosynthetic enzymes
1.1 Properties of polyamines 
Polyamines are polycationic molecules at physiological pH possessing a hydrocarbon 
backbone and multiple amino groups [18, 20]. Polyamines are present in all living organisms, 
with the most common polyamines being putrescine, spermidine and spermine [20]. The 
structures of these naturally occurring polyamines are shown in Figure 1.  
Figure 1: Putrescine, spermidine and spermine chemical structures 
The positive charge on the polyamines is distributed along the entire length of the carbon 
chain. This distinguishes them from the point charges of the other cellular bivalent cations 
(e.g. Ca2+ or Mg2+) and confers polyamines an ability to bind both specifically and non-
specifically to numerous macromolecules, like DNAs, RNAs, membrane proteins, soluble 
proteins, and enzymes, and various small, negatively charged (eg. phosphorylated) molecules 
both in the cytoplasm and nucleus [27]. There is equilibrium between bound and free 
polyamines, the free polyamine pool representing 7-10% of the total cellular polyamine 
content. The concentration of free polyamines that are available for immediate cellular needs, 
is tightly controlled. This is vital for the cells, as a decrease in polyamine concentrations 
inhibits cell proliferation and excess is toxic [28, 29]. Polyamine concentration and 
composition do vary between species and tissues, and high concentrations are generally 
encountered in tissues having high turnover.  
It has been amply studied and documented that polyamines are required for optimal growth 
in prokaryotes, eukaryotes, plants and animals [20, 30]. The vital importance of polyamines 
for normal cellular processes is further emphasized by their roles in maintaining chromatin 
structure, regulating ion-channels, maintaining membrane stability and scavenging free 
radicals [29, 31-34] (summarized in Figure 2). If polyamine metabolism is disturbed, a plethora 
of cellular processes may be affected, including structural changes in chromatin, DNA and 
RNA, transcription, translation, gene expression, autophagy  and stress responsiveness as 
reviewed in [6]. Loss of polyamines consequently, has been shown to inhibit cell proliferation, 
differentiation, and regulate cell death [4, 35]. Confirmed by abundant research and 
corresponding data, the role of polyamines has been associated largely with cell growth and 
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cancer [8, 18, 20, 30], but more recently, also with aging [36-39], memory performance [40], 
neurodegenerative diseases [41] and metabolic diseases [42]. However, despite 
comprehensive studies addressing polyamines, and even after several decades since their 
discovery, a unifying concept to interpret the biochemical function of polyamines is missing. 
The direct and specific molecular functions of the polyamines can be still considered as one of 
the unresolved tasks of molecular cell biology [6]. 
However, a precise and essential function has been reported for spermidine: it is the substrate 
for the production of an unusual amino acid, hypusine [43], which is covalently bound in two-
step process to a single protein reported to date, eukaryotic translation initiation factor 5A 
(eIF5A) [44]. Hypusinated eIF5A is required for efficient synthesis of proteins containing 
regions prone to stalling [45]. These are proteins regulating several key functions in growth 
and development, and thus, essential for the cell metabolism [3].  
Fig. 2 Simplified outline of the cellular mechanisms induced by polyamines (from [39]). 
1.2 Control of the intracellular polyamine content 
The intracellular requirement for polyamines is maintained within a narrow range through the 
combination of a highly regulated metabolic pathway and transport systems. Regulation of 
polyamine levels is highly conserved throughout all known types of life, confirming its 
importance for the cell.  
1.2.1 Polyamine biosynthesis 
The major natural, biologically active polyamines identified in mammalian cells and tissues are 
derived predominantly from the amino acids ornithine and methionine. The established 
biosynthesis pathway (depicted in Figure 3) [8, 20] begins with ornithine decarboxylation, by 
ornithine decarboxylase (ODC), to form putrescine. Spermidine and spermine are formed from 
putrescine via addition of aminopropyl groups. These are donated by the methionine 
derivative decarboxylated S-adenosylmethionine (dcAdoMet) that is in turn produced by S-
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adenosylmethionine decarboxylase (AdoMetDC). Spermidine and spermine synthases 
mediate the addition of aminopropyl groups and the latter two polyamines are catabolized by 
a single enzyme, spermidine/spermine acetyltransferase. In this reaction spermidine and 
spermine are acetylated creating putatively inactive acetylated forms, as acetylation reduces 
their positive charge, preventing their interaction with other molecules [6]. The acetylated 
forms can be converted back to lower polyamines or remain as acetylated polyamines, which 
are easily secreted from the cells. Further conversion to putrescine and spermidine, 
respectively, takes place via oxidizing reaction by polyamine oxidase. These reactions form a 
“polyamine back-conversion cascade” (reviewed in [29]) that allows the cell to regulate 
spermidine and spermine concentrations quickly, and thus, adapt their cellular activity or 
availability.  
Fig. 3 Overview of the polyamine biosynthetic pathway (from [46]). 
1.2.2 Polyamine transport 
Polyamines play a crucial role in the regulation of cell growth and differentiation. Mammalian 
cells fulfill this requirement via the de novo biosynthesis of polyamines and/or through an 
efficient polyamine transport system obtaining polyamines from the extracellular 
environment. Polyamine transport has been detected in almost every model organism and 
are described both in bacteria and single cellular eukaryotes in molecular details [27]. In 
mammalian cells, however, polyamine-specific transport systems are less well understood.  
Three models have been proposed (reviewed in [27, 47]), involving a different variant of the 
endocytic mechanism for the internalization step. After participation of a membrane 
permease polyamines can be processed through a series of endosomes or polyamines bind 
first to heparin sulfate moieties in glypican-1 at the cell membrane and are then internalized 
by endocytosis. It is also suggested that an uptake by caveolar endocytosis where polyamines 
are bound to a putative “polyamine receptor”, could take place in gastrointestinal tissues.  
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The importance of polyamine uptake in malignant cells has been recognized for a long time. 
Transformed cells, in comparison to normal cells, accumulate exogenous polyamines at an 
increased rate [48]. In particular, highly activated polyamine uptake has been shown in several 
tumor cell lines [49]. Despite a lack of full understanding of the polyamine transport system, 
there has been considerable interest of employing it to deliver selectively cytotoxic agents 
into tumor cells [50].  
1.3 Polyamine biosynthetic enzymes 
The concentrations of rate-limiting enzymes in the polyamine synthesis and degradation 
pathways are regulated at different levels, including transcription, translation and protein 
degradation (reviewed in [51-53]). Polyamines can modulate the translation of most of the 
enzymes required for their own biosynthesis and catabolism through feedback mechanisms 
that are unique for each enzyme.  
1.3.1 Ornithine decarboxylase 
L-Ornithine decarboxylase (ODC) catalyzes the first and rate-limiting step in the polyamine
biosynthetic pathway forming putrescine, which is then converted into higher polyamines
spermidine and spermine (see Fig.3). Polyamine content plays important roles in both normal
and neoplastic growth and alterations of polyamine synthesis via changes in ODC content
occur in response to tumor promoters and carcinogens (reviewed in [52]). ODC can alter its
activity in response to many types of cellular perturbations: it is induced in response to growth
stimuli and in cells infected by viruses and under various pathological conditions such as
cancer [8, 11-15, 30, 54, 55]. The loss of ODC gene in mouse embryonic development is shown
to be lethal [56]. All this has guaranteed ODC constant attention not only as a prognostic
factor, but also as a possible target for chemoprevention and therapy [7, 30, 57-59].
ODC is a pyridoxal phosphate (PLP)-dependent amino acid decarboxylase. For the ODC 
activity, the formation of a homodimer (51 kDa) with two active sites is required [60]. There 
are two domains in the ODC monomer, an NH2-terminal domain that binds the cofactor, and 
a COOH-terminal domain. The active site is formed at the dimer interphase between these 
domains [61, 62]. The association between two ODC subunits is quite weak and the dimers 
are in rapid equilibrium with inactive monomers, even under normal physiological conditions 
[60]. 
1.3.1.1 Molecular characteristics of ODC 
The regulation of ODC starts at transcription. The mammalian Odc promoter contains various 
elements (cAMP responsive element, CAAT and LSF motifs, AP-1 and AP-2 sites, GC-rich Sp1 
binding sites, and a TATA box) that allow response to growth factors, hormones and tumor 
promoters [51]. Transcription factors that promote ODC transactivation include the oncogene 
c-myc [63] and NF B [64].
Like many other mRNAs that code for proteins that are important for cell viability and 
proliferation, ODC mRNAs have a long 5ʹ untranslated region (UTR) which contains a strong 
secondary structure (reviewed in [52]). Translation is greatly enhanced by high levels of active 
eIF-4E, which is believed to be involved in the melting of secondary structures on mRNA 5’ 
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UTRs [65]. The 5ʹ UTR contains two additional elements that reduce the efficiency of ODC 
mRNA translation: a small functional upstream open reading frame (uORF) and a GC-rich 
sequence [66-68]. uORFs are strongly inhibitory in vitro and in vivo to translation of ODC [68, 
69], as the presence of them will prevent the ribosome machinery from initiating translation 
at the right codon in an efficient way. Mammalian ODC mRNA translation may also occur in a 
cap-independent manner using an internal ribosome entry site (IRES) [70] allowing translation 
to initiate even when cap-dependent translation is blocked, as in mitosis for instance [71, 72]. 
Polyamine concentration is a strong regulator of ODC translation (Fig. 4). An increase in 
intracellular polyamine levels leads to ODC translation repression, whereas a decrease causes 
translation activation. However, it is not well understood how this translation repression and 
activation by polyamines occurs [6]. RNA-interacting proteins that would act as translational 
repressors to ODC have not been reported. 
Figure 4 Polyamine concentration regulates ODC 
translation. In the presence of high polyamine 
concentration (+) ODC translation is repressed due to an 
uORF in ODC RNA. When polyamine levels decrease (-), ODC 
translation is activated, active ODC dimers can be formed 
and putrescine is synthetized (adapted from [6]). 
1.3.1.2 Regulation of ODC activity 
ODC has many unique features. Due to its very rapid turnover rate it is present only in minute 
amounts in normal growing cells [73]. ODC activity, which is very low in quiescent cells, 
increases upon exposure to trophic stimuli (incl. hormones, various drugs, tissue regeneration 
and serum growth factors) several folds within few hours [18, 74]. Even as stimulated, ODC 
encompasses only a small fraction of the total proteins in the cell. Addition of exogenous 
polyamines to the cells results in a profound and rapid fall in enzymatic activity of ODC [75].  
1.3.1.2.1 Regulation by antizyme 
The previously mentioned negative feedback abolishing the ODC enzymatic activity was 
shown to coincide with an appearance of another protein inhibiting its activity [76] depicted 
in Figure 5. This activity was called anti-enzyme for ODC, or antizyme (AZ) [77, 78]. ODC forms 
1:1 complex with antizyme and its dissociation regenerates ODC activity [78]. The cell culture 
studies showed that there was a strong correlation between antizyme:ODC ratio with the 
degradation rate of ODC [77]. There are four members in the mammalian antizyme gene 
family, antizyme-1 being the best characterized. All members inhibit ODC activity, but are 
expressed differentially or in different abundancy [79]. 
Antizyme mRNA can be found widely, but in very low concentration in most mammalian 
tissues [76, 80]. However, in response to increase in polyamine levels, antizyme protein 
concentration rises rapidly through translational frameshifting [81]. Antizyme is encoded by 
two overlapping open reading frames (ORFs). The first (ORF1) is short, but it contains AUG 
codons that is able to initiate translation. The second (ORF2) encodes most of the protein, but 
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it needs the start codon from ORF1. This is possible by forward frameshifting one base before 
the stop codon of ORF1 is read. Translation continues in the new +1 frame to the end of ORF2 
and produces active full-length protein products [82]. The frameshifting process is highly 
uncommon in most organisms; only three mammalian ODC antizyme genes use this 
translational control mechanism [83]. Neither the exact mechanism, nor how polyamines 
promote this frameshift have been clarified, yet. 
In addition, antizyme can inhibit polyamine uptake and stimulate polyamine secretion [84, 
85]. Again, exact mechanism for this remains unknown. 
Figure 5. Functions of ODC, antizyme and antizyme inhibitor in polyamine metabolism. The ODC dimer catalyzes 
putrescine production, which is converted into spermidine and spermine. Antizyme (AZ) is synthesized via a 
frameshift in its mRNA translation, stimulated by polyamines. Antizyme interacts with ODC bringing it to 
proteasomal degradation, or binds to its inhibitor (AZIN) (from [51]). 
Further, there are inhibitory proteins for antizymes. The first endogenous antizyme inhibitor 
(AZIN1) was first discovered as a protein that binds to antizyme and inhibits several of its 
functions [86]. Although AZIN as highly homologous to ODC was first thought to be a derivative 
of ODC, it was shown that AZIN is a distinct protein lacking the enzymatic activity of ODC [87, 
88]. AZIN functions as a positive regulator of the polyamine pathway by binding to antizyme, 
which hinders formation of the antizyme-ODC complex and consequently suppresses 
antizyme-mediated ODC degradation [87, 89]. High AZIN concentration correlates with 
increased ODC protein levels and activity, enhanced polyamine synthesis and pronounced cell 
proliferation [89]. Interactions between ODC, AZ and AZIN are outlined in Fig. 5. 
1.3.1.2.2 Degradation via the 26S proteasome 
Similar to many short-lived proteins, ODC is degraded by the 26S proteasome [90]. 
Untypically, ODC is not first ubiquitinated, instead ODC antizyme binds to the COOH-end of 
the monomeric form of ODC, preventing thus its dimerization and presents the ODC to the 
26S proteasome for degradation (Fig. 5) [77, 80, 82]. In vivo, in the absence of antizyme, ODC 
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is a substrate for the proteasome, with a half-life of 1-2 hours. When antizyme is present, the 
half-life of ODC is reduced to minutes [77]. 
In summary, ODC is delicately regulated not only at the levels of transcription and translation, 
but also by specific protein interactions controlling its enzymatic activity and degradation 
(summarized in Table 1).  
Table 1. A short summary of ODC regulation 
Responsive elements in Odc 
promoter 
Responsive to Reference 
cAMP responsive element  Hormones [91] 
CAAT and LSF motifs Hormones [92] 
AP-1 and AP-2 sites Growth factors [93] 
GC-rich Sp1 binding sites Multiple stimuli  [94] 
TATA box Multiple stimuli  [95] 
TRE (TPA responsive element) Tumor promoters [96, 97] 
Other regulatory target sequences 
in ODC gene 
Binds to 
E-boxes (CACGTG) Myc/Max transcription factor [63, 98, 99] 
ODC 3ʹ-UTR, between bases 1851 
and 2151  HuR (human antigen R), regulated by mTORC1  [100, 101] 
Translational regulation of ODC 
synthesis Reported action on ODC mRNA 
eIF-4E, long 5'-UTR in mRNA Enhancement of translation by increased levels of eIF-4E [52] 
Short 5'-ORF and GC-rich sequence 
at the 5'-end Strongly inhibitory to translation of ODC [102] 
Polyamines Translation inhibition by excessive polyamines [51] 
Ras activation Stimulatory effect on ODC mRNA content and translation [103] 
ODC protein regulated Reported action on ODC protein 
Antizyme (AZ1, AZ2, AZ3, AZ4) Inhibition and targeting ODC to degradation by complex formation 
[77, 79, 80, 
104] 
Inhibitor of antizyme (AZIs 1-3) Relieves ODC inhibition by binding to AZ [79, 87] 
1.3.1.2.3 ODC inhibition by DFMO 
The recognition that polyamines and ODC activity are a prerequisite for cell growth and that 
polyamine biosynthetic pathway is frequently dysregulated in cancer resulted in the 
development of several inhibitors of this pathway [1, 18, 105]. α- difluoromethylornithine 
(DFMO), an enzyme-activated irreversible inhibitor, is considered as the prototype inhibitor 
of ODC [106]. DFMO is a substrate for ODC and acts by binding to the active site of ODC, 
rendering the enzyme irreversibly inactive [105, 107]. Many studies using DFMO in tissue 
culture have shown near complete depletion of putrescine and spermidine, while effects on 
spermine concentrations differ [108]. This polyamine depletion results in the arrest of cell 
growth, reversible by the addition of exogenous putrescine [105]. Based on its  cytostatic 
rather than cytotoxic effect in vivo, DFMO’s success in cancer therapy showed, however, to 
be less effective than first expected [109, 110]. This could be a result of the poor access 
DFMO has into the cell and high doses that are needed to maintain the inhibitory effect. 
Also, the effect of different compensatory mechanisms, like upregulation of AdoMetDC and
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increased uptake of circulating polyamines cannot be overlooked [1].  
1.3.2 S-adenosylmethionine decarboxylase 
S-adenosylmethionine decarboxylase (AdoMetDC) is the second rate-limiting enzyme in the 
biosynthesis of polyamines [111]. In various mammalian tissues the transition from a 
relatively quiescent state to rapidly proliferating cells is accompanied by large increases not 
only in the levels of ODC, but also AdoMetDC, and their biosynthetic products [112].
AdoMetDC catalyzes the formation of decarboxylated S-adenosylmethionine (dcAdoMet) 
from AdoMet that acts as a donor of aminopropyl groups for the synthesis of spermidine and 
spermine from putrescine. AdoMetDC, like ODC, is a member of a small group of enzymes 
that are dependent on a pyruvoyl group for the decarboxylation process [19, 21, 113]. 
AdoMetDC activity is highly regulated at multiple stages, including transcription, translation, 
proenzyme processing, catalytic activity, and degradation [29].  
1.3.2.1 Regulation of AdoMetDC 
1.3.2.1.1 Transcriptional regulation 
Growth stimulation, e.g. through hormone treatment, tissue regeneration and cellular 
differentiation been shown to associate with increase in AdoMetDC levels [29, 114, 115]. 
Higher polyamines, spermidine and spermine negatively regulate the AdoMetDC gene 
transcription [8, 22, 116]. The exact mechanism, according to which AdoMetDC transcription 
is regulated in mammalian cells has not been fully clarified yet [6]. 
1.3.2.1.2 Translational regulation 
AdoMetDC translation is mediated, as typical for polyamine pathway genes, by uORFs [117]. 
The mammalian uORF that precedes the ORF for AdoMetDC locates in very close vicinity 
downstream of the 5’ cap encoding a peptide: MAGDIS [118]. Upon synthesis of this peptide, 
ribosomes stall, blocking the entry to the AdoMetDC start codon. The length of the ribosome 
stall increases with raising spermidine and spermine concentrations [119]. 
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Figure 6. Regulation of AdoMetDC. Spd and Spm negatively regulate the gene transcription and mRNA 
translation, but increase the degradation of the enzyme. Putrescine activates the enzyme (from [29]). 
1.3.2.1.3 Proenzyme activated by serinolysis 
AdoMetDC is synthesized as an inactive proenzyme (Fig. 6). Through an internal serinolysis 
the proenzyme splits into two non-identical α and β subunits [120, 121]. Serinolysis 
generates a pyruvoyl group at the aminoterminus of the larger α subunit [122, 123] and 
AdoMetDC is rendered more prone for the decarboxylation reaction [46, 113].  
The major regulators of AdoMetDC are polyamine levels. The diamine putrescine binds to the 
dimeric form of the enzyme [46] and affects the activity of mammalian AdoMetDC by 
accelerating the rates of processing of the inactive proenzyme to the mature enzyme [121, 
124] and of decarboxylation by lowering the Km for substrate AdoMet [22]. The roles of
spermidine and spermine are more divergent, but at the end, their effect is more negative
[111].
1.3.3 Half-life 
The half-life of AdoMetDC has been shown to be usually 1-3 hours in most cell lines and tissues 
investigated [125], although a half-life of 3 minutes has been reported in a parasite [126] that 
is the shortest one found in eukaryotes. There is an inverse correlation between AdoMetDC 
half-life and cellular spermidine and spermine [29]: high polyamine levels accelerate 
degradation of AdoMetDC providing another control mechanism to maintain AdoMetDC 
activity and thus, polyamine levels under control [19]. 
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1.3.3.1 Degradation via the 26S proteasome 
Although both AdoMetDC and ODC activities are similarly regulated during cell proliferation, 
their route to the 26S proteasome degradation is different. It has been shown that AdoMetDC 
activity can vanish in a process known as substrate-mediated transamination [125]. In this 
reaction the amine group from the substrate AdoMet is transferred to pyruvoyl cofactor 
transforming it to an alanine [127], and leading not only to the permanent covalent 
inactivation of the enzyme, but also to a conformation change. This makes its ubiquitination 
site more accessible and thus more susceptible to degradation by ubiquitin-dependent 26S 
proteasome machinery [111, 125]. No interaction between AdoMetDC and antizyme has been 
detected [125].  
1.3.3.2 Inhibition of AdoMetDC 
As for ODC, the positive link between polyamine concentrations and cell growth has 
stimulated the development of several inhibitors targeting AdoMetDC [111, 128, 129]. The 
early experiments in mice and the clinical trial showing the antileukaemic effect of 
methylglyoxal bis(guanylhyldrazone) (MGBG) [130, 131] together with its ability to be a potent 
inhibitor of AdoMetDC and thus cell growth [105, 132] have led to development of other 
inhibitors based on the structure of MGBG [105, 133]. Especially one of them, 
SAM486A/CGP48664, was shown to inhibit AdoMetDC more specifically up to 90% and 
decrease the higher polyamine pools [1, 23]. However, besides the enzymatic inhibition, it 
stabilizes AdoMetDC against proteolytic degradation [134].  
1.4 Polyamines and their biosynthetic enzymes in cancer 
The association of polyamines to oncogenic and viral transformation and rapidly induced ODC 
activity upon exposure to growth-promoting factors and chemical carcinogens has been 
known for a long time [8, 30, 112]. Upon oncogenic transformation ODC activity is 
constitutively high ([15-17, 135]. ODC is also a target for c-MYC [63, 136] and the oncogenic 
activation of Ras induces ODC activity promoting malignant transformation and oncogenesis 
[15, 137]. When comparing cancer tissues to their normal counterparts, they were shown to 
have higher concentrations of polyamines, and the inhibitors of polyamine biosynthesis can 
inhibit tumor growth and metastasis significantly [138]. Activation of ODC resulting in 
increased concentrations of polyamines is associated with tumor promotion and progression 
[30, 139]. Furthermore, the expression levels of ODC correlate directly with the potential to 
promote tumorigenesis in both lymphomas and solid tumors [140, 141].  
ODC has dominated the studies on the role of polyamine biosynthetic enzymes in cell growth 
and cancer and much less effort has focused on AdoMetDC. The loss of AdoMetDC gene, 
similarly to ODC, results in very early embryonic lethality in the mouse [142]. AdoMetDC is 
also induced by tumor promoters [141] and frequently dysregulated in cancer, with an 
important role in cell proliferation [1-3, 7]. 
2. Oncogenic transformation models
Protein phosphorylation has been shown to be important in virtually all cellular processes that 
control cell growth, proliferation and survival and are thus involved in development of the 
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transformed phenotype [143]. Kinases are a large family of enzymes, catalyzing the transfer 
of a phosphoryl group from a nucleoside triphosphate donor, such as ATP, to an acceptor 
molecule (reviewed in [144]). Tyrosine kinases are specifically catalyzing the phosphorylation 
of tyrosine residues and protein tyrosine phosphatases (PTPs) removal of it (reviewed in 
[145]).  
The receptor protein tyrosine kinases (RPTK) are a varied family of transmembrane proteins 
that are able to bind to soluble and transmembrane ligands. As a result of ligand binding the 
catalytic activity of the receptor is stimulated leading to a coordinated cascade of signaling 
events that direct at the end a broad range of biological responses [146, 147]. RPTKs are able 
to recruit multiple auxiliary signal transducing proteins, e.g. Src, that act as downstream 
effectors [148]. 
2.1 Src 
c-src was first isolated as the normal cellular homologue of v-src, the gene responsible for
transformation of chick embryo cells by infection with Rous Sarcoma virus [149, 150]. It is the
first proto-oncogene described and one of the first molecules demonstrated to have tyrosine
kinase activity [150-154]. Src is a prototype model for studying cell transformation in general
and understanding signal transduction involving tyrosine phosphorylation [150, 155]. In
addition to Src, nine additional variants closely related to Src have been identified and are
collectively termed Src family kinases (SFKs), Src, Fyn, and Yes being the more ubiquitous
kinases [156, 157]. While Src is the most often implicated SFK in a range of human cancers
[152], it was selected as one model system of transformation for your studies performed in
murine fibroblasts.
2.1.1 Structure of Src 
SFKs are defined by a common modular structure [158]: myristylation at the aminoterminus 
(required for the association with the plasma membrane) (M) [159], variable unique domain 
(U), SH3 and SH2 domains (SH = SRC homology), kinase domain (or catalytic domain), and a C-
terminal tail containing a negative-regulatory tyrosine residue (R).  
Figure 7. Structural comparison of v-Src and c-Src (adapted from [151]). 
The kinase domain at the C-terminal half contains a conserved residue (Tyr 416) in an 
activation loop-region that is involved in autophosphorylation [160]. The autophosphorylation 
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at this position is required for full Src activation. Tyrosine 527 in Src provides one of the key 
regulatory attributes for Src and is a defining feature for all SFKs [161, 162]. v-Src, unlike Src, 
is constitutively active because of the lack of this decisive C-terminal negative-regulatory 
region (Y527 deleted) [163, 164]. As difference to c-src, v-src harbors additional point 
mutations throughout its coding sequence that have the potential to contribute to its high 
intrinsic activity and transforming capability [163]. The structure of v-Src and its cellular 
counterpart is illustrated in Fig. 7. 
The SH-regions encode protein interaction domains: SH3 interacts with specific proline-rich 
sequences [165, 166] and SH2 domains bind to the negative-regulatory Tyr 527 (on kinase 
domain) [167, 168] and to the PDGF-R [169]. The “Src module” (comprising of an SH3, an SH2, 
and a kinase domain) is not only shared with other SFKs, but also with diverse and unrelated 
proteins involved in signal transduction [170, 171]. The concept that modular binding 
domains, like SH2 and SH3, govern the signal-triggered change in the localization of proteins, 
has now proved to be the most important consequence of the activation of tyrosine kinase 
pathways. 
2.1.2 Activation of Src 
Fig. 8 depicts, how the C-terminal tail, and both SH2 and SH3 domains contribute to the 
regulation of the Src kinase via intramolecular interactions [152, 155]. By binding back with its 
C-terminal phosphotyrosine to the SH2 domain, c-Src is inactivated. This and the additional
interaction between the SH3 and the kinase domains form more closed structure in which the
kinase domain cannot access its substrates. Src activation occurs when the C-terminal
phosphotyrosine is removed enabling the opening of the Src molecular structure.
Figure 8. Activation of c-Src (from [157]). 
Phosphorylation of C-terminal phosphotyrosine is carried out by another kinase, the Cellular 
Src Kinase, CSK [172], and for the dephosphorylation the function of various phosphatases like 
Protein Tyrosine Phosphatases (PTPs) and SH2-containing phosphatases (SHPs) have been 
suggested [173-175]. The opening of the molecule frees the SH2 and SH3 domains to interact 
with numerous cellular factors, including receptor tyrosine kinases [176, 177], G-protein-
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coupled receptors [178], and focal adhesion kinase (FAK) [179], (depicted in Fig. 9), among 
many others [180]. The activated Src is a protein of multiple functions and is involved in the 
regulation of normal and oncogenic processes, like proliferation, differentiation, survival, 
motility, and angiogenesis [152, 177].  
2.1.3 Src localization 
The correct localization of Src with the plasma membrane is considered to be requisite for its 
transforming activity [181] (Fig. 9). The autophosphorylation of Tyr419, which occurs when 
Src is targeted to the membrane enabling the interaction with activated receptor tyrosine 
kinases, enhances Src transforming activity to the highest level [182]. 
Figure 9. Simplified view of c-Src regulation by plasma membrane receptors (from [157]). 
2.1.4 Interaction with substrates 
Src applies its effects on tumor-cell behavior through interactions with various substrates and 
binding partners. These initiate various signal transduction cascades that are illustrated 
simplified in Figure 10. Research done on Src has delivered abundant data on signal 
transduction in general, however, the exact function of Src itself within a cell has remained 
ambiguous. 
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Figure 10. Selected signal transduction pathways involving v-Src (from [183]). 
2.2 Ras 
The Ras genes represent some of the earliest described oncogenes, and they and the signal 
transduction pathways induced by them have fundamentally transformed the present 
understanding of cancer biology. Originally identified as a viral component able to induce 
sarcomas in rats [184, 185], and later found to be normal components of the human genome 
[186, 187], Ras genes were shown to transform normal animal [188] and human cells [189, 
190]. Now it is known that Ras alterations contribute to 20-30% of all human cancers and the 
Ras signaling pathway has been identified as the most altered oncogenic network in cancer 
[191]. Ras is the prototype of a larger family of proteins (~150) that are small GTPases 
indicated in regulation of cell growth, proliferation and differentiation [192]. Small GTPases 
are enzymes catalyzing the hydrolysis of guanosine triphosphate (GTP) to guanosine 
disphosphate (GDP) [193]. Ras GTPases cycle between the active GTP-bound state and the 
inactive GDP-bound state; they are inactivated by GTPase activating proteins (GAPs) and 
activated by guanine nucleotide exchange factors (GEFs) [194]. Activated GTP-bound Ras 
binds to and activates in turn a variety of downstream effectors.  
2.2.1 The Ras family 
The Ras gene family consists of three isoforms – Ha- (Harvey), N- (neuroblastoma) and Ki- 
(Kirsten rat sarcoma viral oncogene homolog) ras. Expression of these genes is very abundant 
and conserved across various species, emphasizing their important roles in many normal 
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cellular processes, including proliferation, differentiation, and cell death [195]. These isoforms 
are highly homologous regarding their primary amino acid sequence (~80%) and differ only in 
the C-terminal hypervariable domain [196]. This domain contains sequences that are 
necessary for the Ras proteins to anchor on the cytoplasmic side of the cell membrane [197], 
where each isoform differentially regulates its downstream effectors, resulting in distinct 
alterations both in the strength and the type of signal that is produced [196, 198-200].  
2.2.2 Regulation of Ras 
Oncogenic activating mutations in all three Ras genes are found in 27% of all human cancers 
and have been shown to concentrate at positions 12, 13 and 61 in all of the isoforms (COSMIC 
v90) [201]. The GAP-mediated GTP hydrolysis is defective in mutant Ras resulting in an 
accumulation of constitutively GTP-bound (active) Ras in cells. As the consequence of the 
persistent active Ras, the downstream effector pathways are constantly activated. The 
mutated isoforms can be found in human cancers with different frequencies: K-Ras 
predominates with 85%, followed by 11% of mutated N-Ras and the least mutated H-Ras with 
4%. There is evidence that these mutations do not have only differential oncogenic potencies, 
but also distinct functional consequences [200, 202, 203], adding even more complexity to the 
signaling networks controlled by Ras [201]. 
The normal function of Ras proteins requires them to be post-translationally modified in order 
to localize correctly to their subcellular compartment on the plasma membrane. This 
attachment of Ras proteins to cellular membranes is essential for them to be biologically fully 
functional. The newly synthesized Ras isoforms in cytoplasm undergo several 
posttranslational modifications, like farnesylation, palmitoylation and/or ubiquitination [195, 
204]. These modifications control Ras proteins’ traffic via the ER-Golgi secretory pathway to 
their specific final destinations on the inner side of the plasma membrane [205]. At the plasma 
membrane different Ras isoforms can laterally segregate into spatially distinct and dynamic 
nanoclusters that are the sites for specific effector recruitment and activation, leading further 
to the signal propagation [206]. The membrane attached Ras cycles between inactive GDP-
bound and active GTP-bound stages. Several GEFs (guanidine exchange factors) and a variety 
of GAPs (GTPase activating proteins, which switch off RAS by catalyzing RAS-mediated GTP 
hydrolysis) have been distinguished for Ras [207-209]. Finally, it is the balance between the 
GEFs and GAPs that determines the activation state of Ras and its downstream effector 
pathways [210].  
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Figure 11. Schematic view of Ras activation and signaling taking place at the plasma membrane (from [211]). 
Figure 11 illustrates, how the activated receptor tyrosine kinase (in this case the PDGF 
receptor) [212, 213] upon ligand binding is autophosphorylated, creating docking sites for 
several SH2-domain containing adapter proteins, such as Grb2 (growth factor bound protein 
2) [214] or SHC [215, 216] bind to the activated receptor. Grb2 in turn binds to Sos (an
example of several Ras-GEFs) [207, 209] via its SH3-domains and couples the whole complex
to the plasma membrane, where Ras is also localized. Due to the close vicinity of Sos and Ras,
the GTPase activity of Ras is increased, resulting in replacement of GDP by GTP and thus, Ras
activation [195].
2.2.3 Ras-induced signal transduction pathways 
Ras signaling can be activated not only by a number of cellular receptors including receptor 
tyrosine kinases (RTKs) as depicted above, but also by G-protein coupled receptors (GPCRs) 
and integrin family members (see Fig. 11). Commonly, these receptors initiate Ras signaling 
cascades through assembly of several scaffolding proteins that have the main task of 
mediating conversion of Ras from an inactive GDP-bound form to an active GTP-bound state 
[217]. This induces a conformational shift in the Ras protein enabling it to interact physically 
with several alternative downstream signaling partners.  
The spectrum of possible Ras effectors is broad, but the four main pathways that are activated 
downstream of Ras and previously shown to be relevant for cellular transformation are 
illustrated in Fig. 12: Ras-Raf-MAPK, PI3 kinase, RAL–GDS and phospholipase C (PLC) pathways. 
They have major roles in mediating signals that control cell proliferation, survival, adhesion, 
and motility [192, 195, 203, 218]. 
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Figure 12. Ras-induced signal transduction pathways (adapted from [219]). 
2.2.3.1 Ras-Raf-MAP kinase pathway 
From the various Ras effectors, the first one to be characterized was the protein 
serine/threonine kinase Raf. The activated Ras binds to, and contributes to the activation of, 
the three closely related Raf proteins (c-Raf1, Braf and Araf). The binding of Ras triggers Raf’s 
relocation to the plasma membrane, which is required for its activation [220, 221]. 
Downstream of this, activated Raf phosphorylates and activates a second mitogen-activated 
protein kinase known as MEK – a dual-specificity kinase that is capable of phosphorylating 
both serine/threonine and tyrosine residues, and activating thus the mitogen-activated 
protein kinases (MAPKs) Erk1 and Erk2 (extracellular signal-regulated kinases 1 and 2). Once 
activated, Erk kinases not only phosphorylate cytoplasmic substrates, but can also translocate 
to the nucleus, where they cause the phosphorylation of transcription factors, like AP-1 [222] 
and MYC [223], and lead to the initiation of the immediate and delayed early gene responses. 
Consequently, central cell-cycle regulatory proteins (e.g. D-type cyclins) are expressed, 
enabling cells to proceed through the cell cycle [224]. Hence, Raf activation promotes cell-
cycle progression, at least in contribution of other signals [225]. The Ras-Raf-MAPK pathway 
is reviewed in [150, 195, 226]. 
2.2.3.2 PI3 kinase (PI3K) pathway 
The phosphatidylinositol-3-OH kinases are a large family consisting of several classes and 
isoforms [227, 228]. The classification is based on their variable specificity for substrates and 
differences in structure. The common domain structure for all classes is heterodimer between 
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a p110 catalytic and a p85-type regulatory subunit. Upon activation of RTK a p85-subunit 
attaches to phospho-tyrosine residues and/or other adaptors found on the RTKs. As a result, 
the catalytic subunit p110 is disinhibited and phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3). The direct interaction 
of Ras with the catalytic subunit (p110) of PI3Ks that has translocated to the plasma 
membrane and went through conformational changes, can also lead to activation of this lipid 
kinase [229]. Conversely, the tumor suppressor protein PTEN dephosphorylates PIP3 back to 
PIP2, resulting in termination of signaling [230]. By binding of PIP3 to a large number of 
proteins through the PH (pleckstrin homology) and other domains, PI3K controls the activity 
of a plethora of downstream enzymes. Once PIP3 is formed, it recruits PDK1 (3-
phosphoinositide-dependent protein kinase-1) and AKT (or protein kinase B, PKB) kinases and 
brings them in close proximity, where PDK1 can phosphorylate AKT [231-233]. 
Phosphorylation of many targets by AKT is strongly anti-apoptotic [234] and, hence, an 
important part of the survival signal that is generated by Ras [235]. 
2.2.3.3 Ral-GDS pathway 
Ras-related (Ral) proteins belong to the subfamily within the Ras family of small GTPases and 
through one of its exchange factors Ral-GDS (Ral guanine nucleotide dissociation stimulator), 
Ras is able to stimulate Ral [236, 237]. Activation of Ral-GDS pathway has been implicated in 
activation of phospholipase D1 and together, interacting with PI3K pathway to contribute to 
cell cycle arrest, transcription and vesicle transport [195]. Noteworthy, the activated Ral-GDS 
pathway appears to have more critical function in Ras-induced oncogenesis in human cell lines 
in vitro [238, 239], indicating the difference to murine Ras-transformation models in which 
the Raf-MAPK pathway has the dominant role. Recently shown efficacy of the Raf-MAPK 
pathway inhibition in various KRAS-mutated human tumor cell lines, however, emphasizes the 
emerging importance of this pathway also in the human cells [223, 240].  
2.2.3.4 PLC pathway 
Phosphoinositide-specific phospholipase C proteins (PLCs) are a family of enzymes that 
regulate the hydrolysis of the inner plasma membrane lipid phosphatidylinositol 4,5-
bisphosphate (PIP2) [241]. As a result, two intracellular second messengers, diacylglycerol and 
inositol 1,4,5-trisphosphate (IP3) are produced, and protein kinase C (PKC) is activated and 
internally stored Ca2+ released, respectively.  
Initially, the activation of phospholipase C and the inositol lipid signaling pathways was 
thought to occur primarily by activating heteromeric G proteins or tyrosine kinases [242, 243]. 
Upon mitogen stimulation, like platelet-derived growth factor (PDGF), the 
autophosphorylation of the receptor creates a binding site for the PLCg-isozyme that contains 
SH2- and SH3-domains capable to specifically interact with tyrosine residues [244, 245]. Even 
though the PDGF receptor activation was shown to induce concomitant and rapid increase in 
GTP-bound active Ras, data about the role of Ras in PLCg activation has been contradictory 
[213, 246, 247]. Later, the expansion of the PLC-isozyme family with an isotype epsilon (PLCe) 
has brought clarification. PLCe binds to, and is regulated by, activated Ras [248, 249]. The PLCe 
that contains RA (Ras-association) domains instead of SH-domains, was found to bind Ras in a 
GTP-dependent manner, comparable to the binding of Ras to Raf-1 [248]. Meanwhile, eleven 
mammalian PLC isoforms have been identified with structural differences, which may be 
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linked to the distinct mode of regulation of each isoform [250], creating even more diversity 
to this complex pathway (reviewd in [217]).  
2.2.4 Aberrant Ras-mediated signaling in transformation 
As described above and depicted in Fig 12, Ras oncoprotein has a plethora of effectors and it 
is able to activate multiple downstream signaling pathways. The role of oncogenic Ras in the 
activation of Raf-MAPK signaling pathway both in experimental models and human 
malignancies is richly documented. More than a century after its finding [251] and an excess 
of publications since then have shown that GTP-bound RAS is able to bind and turn on effector 
enzymes activating pathways that control cell proliferation, survival and other aspects of cell 
behavior contributing to the transformed phenotype [196, 205, 217, 231, 252]. The Ras 
pathway has been shown to be one of the most prevalent oncogenic alterations in both 
experimentally induced animal and human tumors [195, 200, 201, 203, 204, 227, 231].  
An important concern perplexing the view of Ras transformation is that the different Ras-
induced pathways have been reported to be mechanistically distinct depending on the species 
and/or cell type. As the Raf-MAPK pathway has been shown to be solely responsible of 
transformation of immortalized mouse fibroblasts [253, 254], its activation is not enough to 
transform intestinal epithelial cells originating from rat [255], human MCF-10A breast cancer 
cell lines [256], or human BJ fibroblasts [238]. However, the identification of mutated BRAF 
leading to the constitutive activation of Raf-MAPK-pathway in melanomas and in lesser extend 
in other human tumors ratifies the importance of this Ras- effector pathway in human 
malignancies [257]. There are also differences in requirements for Ras-induced 
transformation among different cells even of the same species: in human HEK cells concurrent 
activation of PI3K- and Ral-GDS pathways transforms cells, while in human fibroblasts Raf-
MAPK and Ral-GDS pathways need to be perturbated for full transformation [258]. 
Even though research on oncogenic Ras has provided rich and instructive information about 
structure, biochemistry and biology of Ras, many issues are still poorly understood and much 
remains to be elucidated. The structure of the Ras isoforms is very similar, but they appear to 
have distinct effector pathways, which together with their specific and differential membrane 
location or subcellular compartmentalization [217, 259, 260] and in certain cell, tissue or 
species specific context, may even have opposite responses or very different preponderance 
[201, 203, 205, 261-263]. Also, the expression levels of oncogenic Ras impact the degree of 
aberration in signaling (see publication II, [264]) and perhaps through this, phenotypic 
outcome. There is an increasing number and complexity between interactions of the Ras 
effectors and the downstream pathways they induce, including feedback loops and signaling 
redundancy [265-267], making understanding of Ras-signaling network in different context 
even more challenging. 
2.3 Cell transformation in rodent and human cells 
Transformation of a normal cell into a cancerous cell is considered to occur by accumulation 
of genetic errors in a multi-step process [268]. The evidence is now substantial that there are 
differences in rodent and human cell transformation; the type of signaling pathway disturbed 
and how many aberrations are required [269, 270]. This seems to vary according to the cell 
type and tissue and even among the same organism. One of the key reasons for the differential 
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resistance to oncogenic transformation between murine and human cells could be due to 
differences in DNA repair capacity, exerted by expression of TERT (telomerase catalytic 
subunit) [271, 272]. Rangarajan et al [258] have determined that for transformation of normal 
mouse fibroblasts only two signaling pathways need to be perturbated (involving Raf-MAPK 
pathway and p53), instead of six pathways in human fibroblasts. Indeed, several sets of genes 
have been identified to cooperate to transform human fibroblasts, commonly including one 
of the Ras-pathways, c-Myc and telomerase activation, the perturbation of protein 
phosphatase 2A and the inactivation of tumor suppressors, like p53, Rb and PTEN [258, 273-
275]. In this respect there are still unanswered questions, as these gene sets appear not to be 
universal to all human cell lines: some human fibroblasts continue to be refractory to 
transformation even under these conditions [276], suggesting the existence of still 
unidentified factors required for cell transformation specifically in human cells. Consequently, 
there are limitations of rodent experimental systems that are important to keep in mind for 
attempts to apply murine studies of RAS in human malignancies [192, 269, 270]. 
3. Signal transduction
3.1 Function of protein kinases and phosphatases 
Protein phosphorylation and dephosphorylation, catalyzed by kinases and phosphatases, can 
modulate the function of a protein in various ways; its biological activity is increased or 
decreased, it can be stabilized or marked for destruction, it can change its subcellular 
localization or assembly of signaling complexes is disrupted [277]. The simple, sensitive and 
dynamic way of regulation of proteins by phosphorylation on serine, threonine and tyrosine 
residues have made it the most general control mechanism in eukaryotic cells, able to 
influence pathways leading from cell division to cell death [278]. The most of the 
phosphorylation events occur on serine and threonine residues, whereas tyrosine 
phosphorylation is considerably rarer post-translational modification [279]. The discovery of 
protein kinases associated with viral transforming proteins and the capacity to phosphorylate 
tyrosine residues suggested that tyrosine phosphorylation plays a significant role in growth 
control [153, 280]. Aberrant phosphorylation is acknowledged now as a cause or consequence 
of many human diseases, and oncogenic mutations resulting in RTK overexpression and/or 
constitutive activation have been shown to be associated with many types of cancers [277, 
281]. 
Much less attention has been paid to the counter players of the balance, namely protein 
phosphatases [282-284]. Protein tyrosine phosphatases (PTPs) comprise a large and 
structurally diverse family that is divided in receptor-like or non-receptor-like forms [285]. The 
receptor-like PTPs traverse plasma membrane and have extracellular domains resembling 
those of cellular adhesion molecules with immunoglobulin-like domains and fibronectin-III-
like repeats and cytoplasmic part with PTP domains containing catalytic domain responsible 
for dephosphorylating activity. In non-receptor PTPs the catalytic domain is often linked to 
domains that mediate protein-protein interactions, like SH2-domains in SHP2 [286], 
connecting it physically to e.g. the most RTKs like PDGF receptors (see later). 
As PTPs can antagonize RTK signaling by direct receptor dephosphorylation, they have been 
almost naturally considered as potential tumor suppressors and indeed, several inactivating 
mutations or other tumor suppressive evidence have been identified in human cancers or in 
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vivo models [287, 288]. The PTPs can exhibit also oncogenic activity, exemplified by SHP2 that 
is required for the activation of MAPK pathway upon growth factor stimulation and is 
considered as a proto-oncogene [282, 286, 289]. 
Like tyrosine phosphorylated proteins the serine/threonine phosphorylated proteins have 
specific phosphatases (PSPs) that are reversing the actions of serine/threonine kinases [290]. 
One of the three major PSP-families is the family of phosphoprotein phosphatases (PPP), in 
which the catalytic subunit associates with a large number of regulatory subunits enhancing 
the coverage of broader spectrum of targets. One important representative of the PPP-family 
is PP2A whose several isoforms have been shown to function mainly as tumor suppressors 
[291], but also tumor promoting roles, depending on the context of the cancer cell, have been 
reported [292, 293]. Interestingly, CIP2A, the cancerous inhibitor of PP2A that has been 
observed overexpressed or constitutively activated in various human cancers [294, 295], has 
proven to be an attractive target for designing new cancer therapies (summarized in [296]). 
3.2 PDGF-signaling pathway 
The platelet-derived growth factor (PDGF) receptor is one of the best-characterized growth 
factor receptors [150, 212, 297, 298]. PDGF isoforms stimulate growth, survival and motility 
of mesenchymal cells and by activating their receptors, mediate central signals during the 
embryonal development and control tissue homeostasis in the adults [299, 300]. The 
overactivity of PDGF receptors has been found to drive tumor cell growth [301]. As several 
signal-transducing proteins that are thought to be involved in PDGF-induced signaling are well 
characterized and as both Src family kinases and Ras proteins are involved in PDGF-induced 
signaling in normal cells, it was our choice of research model to study this signal transduction 
pathway in transformed cells. 
3.2.1 PDGF isoforms 
The PDGF family of growth factors is composed of four different polypeptide chains encoded 
by four different genes [301, 302]. The classical PDGF chains, PDGF-A and PDGF-B, undergo 
intracellular activation during transport in the exocytic pathway and more novel PDGF-C and 
PDGF-D chains require activation by extracellular proteases [212, 302]. The four PDGF chains 
assemble into dimers via homo- or heterodimerization (Fig. 13, upper part), and five different 
dimeric isoforms have been described: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD. 
The later discovered PDGF isoforms (CC and DD) will not be discussed, as they have not been 
relevant for the work presented here.  
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Figure 13. The active PDGF receptor complex consists of two chains associated with one dimeric ligand (redrawn 
from [212]). 
3.2.2 PDGF receptors 
PDGFR is the member of the type III class of RTK receptors that are typically formed by five Ig-
like domains extracellularly and a split kinase domain intracellularly [212]. Ligand binding 
results both in homo- and in heterodimerization of PDGF-a and -b receptors (Fig. 13, lower 
part). The dimerization is a central step in receptor activation since it brings the intracellular 
parts of the receptors close to each other promoting autophosphorylation of certain tyrosine 
residues in the intracellular parts of the receptors. The PDGF polypeptide chains bind to the 
receptors with different affinities and different dimeric receptor complexes having 
overlapping, but slightly dissimilar signaling abilities. The receptors have several 
autophosphorylation sites (Fig. 14) that serve critical functions: the conformation changes of 
the intracellular parts of the receptors promote receptor activation, and provide docking sites 
for SH2-domain-containing signal transduction molecules [212, 298]. 
3.2.3 PDGF receptor induced signaling 
Several SH2-domain-containing molecules selectively bind to autophosphorylated residues in 
the PDGF receptors and become activated by them (reviewed in [212, 298, 299] and depicted 
in Fig. 14): tyrosine kinases of the Src family [303], the SHP-2 tyrosine phosphatase (or Syp) 
[304, 305], phospholipase C-γ (PLC-γ) [244] and the Ras-GAP [306] are molecules with intrinsic 
enzymatic activities. The receptors bind directly also STATs (signal transducers and activators 
of transcription) that translocate after their activation into the nucleus to function there as 
transcription factors [307-309]. Adaptor molecules without intrinsic enzymatic activities, like 
the regulatory subunit p85 of the phosphatidylinositol 3ʹ -kinase (PI3K) [310], which forms 
complex with the p110 catalytic subunit, and Grb2 [311] which binds and phosphorylates the 
nucleotide exchange molecule SOS1 [312] have determined docking sites on the intracellular 
part of the receptor as well. Additionally, PDGF receptors bind to and phosphorylate other 
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adapter molecules, e.g. Shc [313], and Nck [314, 315], which in turn promote further 
interactions with various different downstream signaling molecules. 
Figure 14. PDGF receptors present several possible sites for autophosphorylation (PDGFR-a 10 and PDGFR-b 11) 
that can bind SH2-containing signaling molecules (redrawn from [212]). 
The phosphorylation of PDGF receptors at multiple sites causes the binding of various 
signaling molecules that form complexes with other molecules leading finally to the activation 
of signaling pathways illustrated in Fig. 15. These pathways conduct the signal from the plasma 
membrane to the nucleus, where its effect is exerted on cell proliferation and survival, as well 
as on actin reorganization and cell migration.   
Figure 15. Signaling network from the activated PDGFRb consists of multiple interconnected pathways from 
receptors to the nucleus (from [25]). 
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3.3 JAK/STAT pathway 
Janus tyrosine kinase (JAK) family of proteins and signal transducers and activators of 
transcription (STATs) comprise a signaling pathway that has been shown to exert a role in 
development, proliferation, differentiation, and survival of cancer cell [308, 309]. Compared 
to other cell signaling pathways, JAK/STAT pathway seems with relatively few components, 
simple and straightforward; the mammalian JAK family contains four, and STAT family seven 
members that act mainly as transcription factors [316, 317]. It is a highly conserved pathway 
and observed in a wide range of species, activated primarily by cytokines [318], but also by 
growth factors [307]. JAKs belong to the family of non-receptor PTKs and lack SH2 or SH3 
domains, but contain five upstream repeats referred to as JAK homology (JH) domains and 
two PTK-like domains in the C-terminal half of the protein. These two almost identical 
phosphate-transferring domains have given the non-receptor kinases the name “Janus”: one 
domain exhibits the kinase activity, while the other negatively regulates the kinase activity of 
the first [319]. The supposed relative simplicity of the pathway has been found over the years 
to be more complex due the inter-pathway cross-talks, like the effect of STAT3 activation on 
Ras and PI3K/Akt pathways [320], and the connections of JAK2 to PI3K and ERK pathways 
[321]. 
Treatment of cells with PDGF and EGF has been shown to specifically induce STAT1 (p91/p84 
or p91) and STAT3, which become phosphorylated on tyrosine residues by JAKs and 
translocate into the nucleus where they act as transcription factors [307, 316, 317, 322]. 
However, details about these interactions have remained limited. 
The role and significance of dysregulated STAT signaling in cancer biology have been studied 
intensively. According to major evidence STAT1 activation has rather a suppressive function 
in cancer cells [323]. Yet, some experiments and clinical studies suggest that STAT1 also exerts 
tumor promoter effects under specific conditions, and dependent on the cellular context, 
STAT1 can have either oncogenic or tumor suppressive function in the same cell type [324].  
Several human cancers present constitutive overexpression or tyrosine phosphorylation of 
STAT3 [325] that supports transformation of various cell culture and animal models [326]. 
Constitutively active mutants of Stat3 have been shown to be able to transform normal cells 
into cancer cells [327]. 
3.4 S6 kinase pathway 
The interest towards the possible role of S6K in transformation was evoked by the finding that 
Ras-transformed cells showed increased ribosomal protein S6 phosphorylation [328]. As part 
of the 40S ribosomal subunit it is supposed to be involved in regulating translation and mouse 
model studies show its involvement in the regulation of cell proliferation [329]. The enzymes 
p70-S6K1 and p85-S6K1 (two isoforms of the same enzyme) that are activated by a complex 
phosphorylation event [330] are responsible for the S6 phosphorylation, however, 
independent of Ras and MAPK pathway [331]. 
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3.5 p38 MAP kinase pathway 
p38 MAP kinase is a member of MAP kinase family that is activated in response to a variety 
of extracellular stimuli including stress, cytokines and growth factors (like PDGF) [332, 333]. 
It has been shown to phosphorylate several transcription factors, e.g. ATF-2, STAT-1 or the 
Max/Myc complex [333] and indirectly regulate activating protein-1 (AP-1) activity [334]. 
Although one of the major functions of the p38 kinase pathway is regulation of inflammation 
and apoptosis, in many cases the biological consequences of p38 kinase activation overlap 
with those of ERKs in mediation of cell growth and differentiation [335, 336]. p38 MAP 
kinase has been linked to the normal and oncogenic activity of Ras [337]. 
3.6 JNK pathway 
Jun N-terminal kinases or JNKs are involved in a wide array of signaling events underlying not 
only cell proliferation and cell death (Fig. 16), but also embryonic development, neuronal 
functions, or immunity [338]. Initially Jun kinase was identified as a member of the pp54 
microtubule associated protein-2 kinases [339] and subsequently characterized as stress 
activated kinase preferentially phosphorylating and stimulating the activity of the 
transcription factor c-Jun [340]. The mammalian JNK proteins are encoded by three genes, 
which are alternatively spliced and give rise at least to 10 isoforms [341], JNK1 and JNK2 being 
more ubiquitous, whereas JNK3 is mainly found in the brain. JNK activation is regulated by 
phosphorylation on both threonine and tyrosine residues by a dual-specificity MAPK kinase 
(MAPKK). Two MAPKKs, MKK4 (also known as SAPK/Erk kinase (SEK1) or Jun kinase kinase 
(JNKK)), and MKK7, have been identified as JNK activators. The protein kinases that have been 
reported to act as MAPKKKs (MAP3Ks) for the JNK signaling pathway include the MEK/ERK 
kinase (MEKK) group, the MLK group, TPL-2, ASK1, and TAK1 [342] (see Fig. 18). 
Figure 16. JNK-regulated pathways in cell transformation (redrawn from [343]). 
A major JNK target is the transcription factor AP1, which is composed of Fos and Jun family 
members [340]. JNK was found to bind the NH2-terminal activation domain of c-Jun [344] and 
to phosphorylate c-Jun on Ser-63 and Ser-73 [345]. The phosphorylation of these specific 
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positions increases transcription activity of c-Jun [345, 346]. The oncogenic functions of JNKs 
are mostly based on the ability phosphorylate c-Jun, leading to activation of AP1 [340, 347]. 
3.7 Activator protein 1 (AP-1) 
The AP-1 complex is composed of multiple homodimeric and heterodimeric protein 
complexes involving members of the Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1and 
Fra-2) families and it can heterodimerize also with other transcription factors such as 
members of the ATF/CREB and Maf/Nrl subfamilies [348-351]. These are structurally similar 
and functionally related basic leucine zipper (bZIP) proteins, forming the required dimers 
through the bZIP domain [352]. Dimerization brings the basic regions together and produces 
thus an adjoining interface able to interact with specific DNA sites [353]. The dimers recognize 
either TPA response (5’-TGA G/C TCA-3’) or CRE elements (cAMP response elements) on DNA, 
with different affinity and sequence specificity [354]. AP-1 recognition sites have been found 
in many enhancer/promoter elements [355]. Once bound to DNA, the AP-1 complexes 
regulate transcription either by activating or repressing target gene transcription, each dimer 
differing in their activity depending on the cellular context. The AP-1-induced gene 
transcription is part of the regulation of a variety of critical cellular processes including cell 
proliferation, cell differentiation, cytokine production, apoptosis and oncogenesis [351, 356]. 
3.7.1 c-Jun 
c-jun, the cellular homolog of a v-jun oncogene that was originally isolated from avian sarcoma
virus 17 (ASV17) [357], encodes a 39 kDa nuclear phosphoprotein c-Jun [358, 359]. It is the
most potent activator of the AP-1 family [340]. It has been suggested that c-Jun can function
as a central link in the pathway coupling the signals from the cell membrane to the regulation
of various genes and ultimately to the growth of cells. Various activating signals, like tumor
promoters, growth factors or stress stimuli promote signal transduction pathways that can
rapidly change the phosphorylation state of c-Jun and thus, significantly enhance the DNA
binding and transcription activity of c-Jun [360-363].
There are five serine and threonine residues of c-Jun that can be phosphorylated [364]: three 
upstream of the DNA-binding domain and two within the transactivation domain (Fig. 17A). 
When the more C-terminal sites are dephosphorylated, the DNA-binding affinity of c-Jun is 
increased. The phosphorylation at Ser63 and Ser73 within the transactivation domain are 
important for the transcriptional activity of c-Jun [346, 365]. 
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Figure 17. Phosphorylation regulates c-Jun expression and activity (A) and regulatory circuit between c-Jun and 
AP-1 (B) (from [366]). 
In resting cells c-Jun is phosphorylated on the residues near to the DNA binding domain, and 
thus, silent. Upon stimulation these sites are dephosphorylated allowing interaction with TRE 
sequences in target genes. Serum and growth factor stimuli have been shown to induce AP-1 
by activating the ERK subgroup of MAPKs through a twist via S6 kinase (Fig. 18). When 
glycogen synthase kinase 3 (GSK3) and casein kinase 2 (CK2) phosphorylate c-Jun at its C-
termini, c-Jun is kept in an inactive, non-DNA-binding state [367]. While ERK can activate S6K, 
which in turn phosphorylates GSK-3 at serine-21, results this in its inactivation [368]. Hence, 
ERK, by acting through the S6K-GSK3 cascades, causes c-Jun C-terminal dephosphorylation 
near the DNA-binding domain and increases its DNA binding activity. The ERK1 and 2 have 
been shown to be able to bind and phosphorylate the C-terminal part of c-Jun directly, but 
this does not correlate with the c-Jun activation [369].    
Activation of c-Jun through the JNK cascade is another important post-translational 
mechanism to control c-Jun [370] (Fig. 18). Activated JNKs translocate to the nucleus, where 
they bind to a specific region within the c-Jun transactivation domain and phosphorylate c-
Jun on serines 63/73 and threonines 91/93 [371]. This N-terminal phosphorylation weakens 
also c-Jun’s interaction with a histone deacetylase-containing inhibitory complex [372] and 
thereby its ability to activate transcription upon homodimerization or heterodimerization with 
c-Fos is potentiated [373-375].
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Figure 18. c-Jun can be phosphorylated by both JNK and ERK pathways (from [366]). 
Interestingly, the specific binding of JNK to c-Jun explains why v-Jun, with conserved Ser63/73, 
but without the JNK binding domain, can resist the TPA-induced N-terminal phosphorylation 
[376, 377]. However, the lack of JNK docking domain also eliminates v-Jun binding to the 
repressor complex [372] that is suggested to contribute more to viral Jun oncogenicity than 
missing binding to JNK [378]. By this mean, viral Jun is disconnected from the tight controls 
regulating c-Jun; it is constitutively active and oncogenic.  
Figure 19. Deregulated Jun. a) Cellular Jun and b) viral version of Jun (from [377]). 
The phosphorylated c-Jun may be a trigger for AP-1 activation, but as the phospho-c-Jun 
proteins are relatively unstable and exist only transiently in the cells, their role in maintaining 
the sustained AP-1 activity that is required for many biological activities has been questioned 
[379, 380]. Interesting observations have suggested the existence of a regulatory circuit, in 
which AP-1 activates the c-Jun gene expression that in turn further enhances AP-1, thereby 
potentiating its own gene activation [381-383] (Fig. 17B). By this kind of autocrine circuit c-
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Jun can both prolong and amplify AP-1 activity. Accordingly, AP-1 activity is sustained and 
long-lasting biological outcomes can be maintained [381]. 
3.7.2 c-Jun in tumorigenesis 
In view of the pivotal role of c-Jun in mediating the effects of various tumor promoting factors 
and the already known ability of v-Jun to transform, it was not surprising that uncontrolled 
expression of normal c-Jun protein as well transformed mammalian cells [384, 385]. 
Furthermore, it has been shown that c-jun as a single gene with normal coding potential can 
transform an immortalized rat fibroblasts [384] and over-expression of wild type c-Jun 
transforms chick embryo fibroblasts [386]. Moreover, c-Jun is required for transformation by 
other oncogenes such as src, ras and raf [348, 385, 387-390]. 
The activity of the transcription factor c-Jun is increased in several human cancers [340]. 
Interestingly, it has been also shown that c-Jun activating phosphorylation is a direct and 
central part in the development of colorectal cancer [391] and dysregulation of Jun by 
amplification and overexpression leads to highly aggressive human sarcomas [392].  
4. Tumor angiogenesis
It is now well established and broadly documented that unrestricted growth of solid tumors 
beyond 2-3 mm in diameter is dependent upon vascularization, an event required for tissues 
to grant oxygen, nutrient and waste disposal [393, 394]. The early activation of angiogenic 
processes is compulsory for sustaining the tumor cell proliferation and vessel network 
functions. Later in the tumor development this serves as a route to disseminate cells to distant 
sites, promoting metastasis [395, 396]. 
4.1 Capillary structure 
The basic structure of a vessel wall is depicted in Fig. 20 [397]. Newly emerging vessels consist 
of a tube of endothelial cells (Fig. 20a) that mature to capillaries, when basement membrane 
and pericytes within are covering the tubes (Fig. 20b) [398]. Because of their wall structure 
functioning as an endothelial barrier that is highly permeable to small water- and lipid-soluble 
molecules and their large surface area, capillary network forms the main site of exchange of 
nutrients, gases, and water between bloodstream and tissues [399]. The capillary endothelial 
layer can be naturally continuous, fenestrated or discontinuous, depending on organ or tissue 
type [398]. In comparison to capillaries, more mature arteries and veins have already an 
increased coverage layer of mural cells (Fig. 20c). However, extravasation of cells and 
macromolecules from the blood typically occurs from these postcapillary venules [400]. The 
walls of larger vessels differ from the walls of arterioles and venules by consisting of three 
clearly specialized layers (Fig. 20d). Due to the smooth muscle cells within and elastic laminae, 
this type of vessels have already more defined diameter and better control over blood flow 
[397, 398].  
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Figure 20. Wall structures of growing versus mature vessels. a) Nascent vessel, b) Capillaries consist of endothelial 
cell tube surrounded with basement membrane with a thin layer of pericytes embedded in it. c) Mural cells, like 
pericytes add a stabilizing layer to capillaries. d) The larger vessels wall are composed of three specialized layers 
that provide better control of blood flow (adapted from [397]). 
Normal physiological angiogenic responses follow a structural hierarchy: perivascular cells 
lose their association with the endothelium, endothelial junctions become leaky and finally 
the basement membrane is modified [401, 402]. Tumor angiogenesis, instead, is dysregulated 
as it does not follow any organized process and produces poorly formed blood vessels with 
multiple abnormalities. For example, a hierarchical assembly is missing, vessels have irregular 
diameters, they are highly tortuous, randomly branched and endothelial barrier function is 
defective [397, 402]. Tumor vessels can have abnormal organization of pericyte coat and 
basement membrane might be incomplete [403, 404]. Although the molecular control 
systems leading to these abnormalities are not fully understood, it is assumable that they are 
a result of the bizarre tumor microenvironment created by deregulated growth factors 
combined with hypoxic and metabolic disturbances. 
4.2 Mechanisms underlying angiogenesis 
To date, several mechanisms have been shown to be employed in the neovascularization 
process of the tumors, some originally identified to contribute normal and physiological 
angiogenesis [405]. It seems, however, in pathological neovascularization the mechanisms are 
not mutually exclusive and act somewhat simultaneously. These mechanisms are depicted 
and reviewed in the work of Ronca et al [394] (Fig. 21).  
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Figure 21. Physiological and tumor neovascularization (adapted from [394]). 
4.2.1 Vasculogenesis 
Vasculogenesis together with sprouting angiogenesis are prototypical mechanisms of 
vascularization, known to form and remodel vessels during development, and to get 
reactivated during tumor progression. Vasculogenesis describes a process, where vascular 
progenitor cells differentiate and proliferate within a previously avascular tissue, and then 
merge into a crude tubular network [406]. During angiogenic remodeling the initial network 
is modified, interconnecting the branching patterns, maturing vessels, and finally, forming 
functional vasculature [407]. 
4.2.2 Sprouting angiogenesis 
A process of angiogenic sprouting refers to a multistep model in which sprouting from existing 
vessels creates new capillary vessels into a previously avascular tissue [394, 408]. It is an 
intensive interplay between extracellular matrix components, cells, and soluble factors [394, 
409]. At first, proangiogenic factors (like VEGF) activate endothelial cells toward invasive and 
motile behavior that induces destabilization of the endothelial-pericyte contacts, leading to 
the remodeling of the basement membrane. This in turn, allows the endothelial cells at the 
cell’s front or leading-edge to form filopodia [410] and migrate through the extracellular 
matrix. The cells at the leading-edge (or migrating tip cells) are followed by highly proliferative 
endothelial cells located at the stalk of the angiogenic sprout. Vessels formed by sprouting are 
again initially immature and must further develop. They are the stalk cells that are responsible 
for the tube and branch formation and for the recruitment of pericytes for stabilization.  
4.2.3 Intussusceptive angiogenesis (vessel splitting) 
The concept of vessel intussusception or splitting angiogenesis was originally reported by 
Caduff et al [411]. In this type of vessel formation, the wall of pre-existing capillary extends 
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into the lumen and splits a single vessel in two. The proposed mechanisms involved in the 
formation of split vessels is described in detail in ref [412]. 
Interestingly, during intussusception, neither endothelial cell proliferation or large basement 
membrane degradation is required. This is metabolically less demanding and occurs more 
rapidly compared to sprouting angiogenesis, and can, thus, respond faster to an oxygen 
demand in a growing tissue [413]. Many human tumors display vessel splitting (see refs in 
[394]) and angiogenic switch from sprouting to intussusceptive angiogenesis has been stated 
in relapsing tumors after irradiation or anti-angiogenic therapy, and may represent an 
adaptive tumor-protective response to treatment [394, 414]. 
4.2.4 Vascular co-option 
In vascular co-option or vessel “hijacking” tumor cells surround host vessels and encompass 
them to their own purposes [415]. This eliminates the need for neoangiogenesis (tumors are 
therefore called nonangiogenic), so the co-opted vessels lack the typical abnormal features of 
tumor vasculature, making them less prone to respond to antiangiogenic therapy [394, 416]. 
Mainly the tumors in the highly vascularized tissues (like liver, lung and brain tissues) have 
been shown to exploit vascular co-option as a blood supply [394]. 
4.2.5 Endothelial progenitor cells 
Endothelial progenitor cells are residing in a stem cell niche in the bone marrow. From there 
they are mobilized to the peripheral blood and the tumor sites by various cytokines and 
proteolytic enzymes [394]. On the site of tumor vascularization endothelial progenitor cells 
differentiate into endothelial cells resulting in angiogenesis [417, 418]. Increasing amounts of 
the endothelial progenitor cells have been observed also in many cancers [419, 420]. Even 
though the concept [417] that endothelial progenitor cells are not only involved in embryonic 
development but also contribute to adult vasculogenesis has been intensively studied, its role 
in tumorigenesis has remained unclear [394]. This could be due to the appropriate definition 
for endothelial progenitor cells, their origin and other characteristics that is still missing.  
4.2.6 Cancer stem cells 
Cancer stem cells are defined as rare immortal cells within a tumor that can both self-renew 
by dividing and give rise to many cell types that comprise the tumor [421]. Recent studies have 
suggested that cancer stem cells could also differentiate to endothelial cells and provide 
endothelial lining in human cancers [422, 423]. This hypothesis was supported by the finding 
that the same mutation of the original tumor cell could be found in the subpopulation of 
endothelial cells [422]. 
4.2.7 Vasculogenic mimicry 
The term vasculogenic mimicry has been described originally as very pluripotent cancer cells’ 
ability to form extracellular matrix-rich networks in 3D culture [424]. They are called 
vasculogenic even though these pathways are not formed of the pre-existing vessels, but are 
able to distribute plasma and may contain red blood cells. However, the channels are not 
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blood vessels, they just mimic the function of vessels [425]. The channels were found to be 
lined with tumor cells instead of endothelial cells and were rich in laminin [424, 426]. 
To date, vasculogenic mimicry is distinguished in the tumor samples using 
immunohistochemistry staining positive for both CD31 and periodic acid Schiff (PAS) stain, 
CD31 being a marker for endothelial cells and PAS to identify extracellular matrix. Two types 
of vasculogenic mimicry has been described in aggressive tumors: the tubular type is 
composed of non-endothelial cell-lined blood tubes, confusing them with morphologically 
similar endothelial cell-lined blood vessels [427] and the patterned matrix type, comprising of 
a basement membrane rich in fibronectin, collagens and laminin, and where the membrane 
is surrounded directly by tumor cells [428]. 
The initial description of “highly patterned vascular tubes formed by aggressive uveal 
melanoma cells without the endothelial cell lining” by Maniotis et al [424], was received by 
skepticism [429, 430]. Since then, however, vasculogenic mimicry has been described in 
numerous types of cancers, including breast, lung, colon and ovarian carcinoma [431]. Further, 
its presence in melanomas [432] and other cancers [433] has been shown to associate with a 
poor prognosis. Moreover, it is suggested that both angiogenesis and vasculogenic mimicry 
are coordinately used in tumor tissues [434]. In tumor areas, where vasculogenic mimicry is 
part of the functional plasma circulation, cancer cells from the tumor cell-lined channels have 
a facilitated access via endothelial-lined vessels out of the tumor into the blood circulation, 
contributing thus to invasion and metastasis (Fig. 22).  
Figure 22. Melanoma and its extracellular matrix containing both endothelial and tumor-cell-lined fluid-
containing channels (from [435]). Melanoma (blue cells) contain endothelium-lined vessels (pink) in close contact 
to fluid-containing matrix formed by tumor cells (green). Tumor cell-induced remodeling of the vasculature can 
lead to the accumulation of red blood cells (red) outside of the vasculature. The biological implications or the 
relationship of the systems (marked “?”) still need to be clarified.  
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Epithelial-mesenchymal transition (EMT) or cancer stem cells (CSC) have been suggested as 
possible mechanisms for the development of vasculogenic mimicry patterns [436] and the list 
of contributing protein factors (such as VE-cadherin, matrix metalloproteinases, ephrin type-
A receptor 2, and NOTCH proteins) is growing [431, 435]. Despite remarkable advances, the 
key mechanisms of vasculogenic mimicry have remained ambiguous.  
4.2.8 Mosaic vessels 
Tumor vessels that constitute of both endothelial and cancer cells that are in direct contact 
with the vessel lumen, have been described as mosaic [437, 438]. Mosaic vessels have been 
identified in experimentally induced mouse xenocrafts and human biopsies of colon 
carcinoma [439] and more recently in MYCN amplified neuroblastomas [440] and 
glioblastomas [422, 423]. The association of mosaic vessels to very aggressively growing 
tumors could be an indication for invasive and metastatic tumor growth [439, 441]. Also, the 
participation of tumor cell on the vessel lining would have important consequences for 
therapeutics design that targets the tumor vasculature. 
Di Tomaso et al [441] suggest several possibilities how mosaic vessels could originate. “First, 
endothelial migration during rapid vessel growth occurs without sufficient endothelial 
proliferation to complete the endothelial lining. Second, endothelial cells shed from the vessel 
lining, leaving underlying tumor cells exposed. Third, surrounding tumor cells invade the 
vessel wall and displace endothelial cells from the lining. And fourth, mosaic regions are lined 
by abnormal endothelial cells that do not express common endothelial markers, and cannot 
be detected”. Improved detection of endothelial cells, combined with consensus on the 
endothelial markers and with a better understanding of the plastic nature of tumor cells 
together with their interaction with surrounding matrix could bring clarification to this 
complex system in the future. 
Additionally, an intriguing possibility has been proposed that the PAS- and laminin-rich 
channel network described above, after being an early survival mechanism for the acute needs 
of the growing tumor, could be replaced by endothelial cells from the nearby angiogenic 
vessels, the bone marrow or from the circulating endothelial precursor cells that would later 
cover the exposed tumor cells on the vessel wall [417, 426, 438, 442]. Mosaic vessels would 
then in this case be a temporary phenomenon, on the way towards more stable tubular 
structures. 
4.3 Angiogenic switch 
The induction of tumor angiogenesis, termed the “angiogenic switch” is a hallmark of cancer 
[281]. It is driven by the growing tumors’ requirement for oxygen supply and waste removal 
[393, 394]. The observations that tumors implanted into an avascular region were able to elicit 
the ingrowth of new capillaries, suggested that they release diffusible factors, able to activate 
a quiescent vasculature [443]. This has led to a finding of several tumor angiogenesis 
stimulating factors, such as vascular endothelial (VEGF), fibroblast (FGF), platelet-derived 
(PDGF) and epidermal growth factors (EGF) [444]. Factors inhibitory to angiogenesis are an 
equally important component of the switch. The significance of these negative regulators of 
angiogenesis became obvious in experiments that compared cell lines containing or missing 
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the tumor suppressor gene [445, 446]. The nontumorigenic cell line released high levels of a 
potent angiogenesis inhibitor, while tumorigenic cell line released much less [446]. In general, 
the levels of activators and inhibitors comprising the angiogenic balance, determine whether 
an endothelial cell will be in quiescent or an angiogenic state is induced. It is assumed that the 
changes in this balance are the triggers of the angiogenic switch.  
In physiological and normal angiogenesis, the balance between pro- and anti-angiogenic 
signals is tightly regulated: new vessels mature rapidly, become stable and return back to 
quiescence. Normal vasculature is well organized into definitive venules, arterioles and 
capillaries, in which the metabolic needs of the tissue determine the vessel density (Fig. 23 
left). However, after angiogenic switch, tumor blood vessels remain active, continue 
uncontrolled growth and result in irregularly shaped, dilated and tortuous vascular networks 
with numerous dead ends [397, 444] (Fig. 23 right). Overexpression of growth factors, like 
vascular endothelial growth factor (VEGF) can make the vessels leaky and tumors hemorrhagic 
[447]. Also, perivascular cells that have been embedded in endothelium, become less 
abundant or more loosely attached [403].  
Figure 23. Highly simplified view of normal versus tumor-induced vascular bed (adapted from [397]). a) Normal 
vascular bed has a regular appearance and physiological angiogenic responses follow a structural hierarchy. b) 
Activated angiogenesis and vessel remodeling result in abnormal vascular bed leading to chaotic blood flow in 
tumors.  
4.3.1 Proangiogenic molecules 
Vascular endothelial growth factor (VEGF) (also termed VEGF-A) belongs to a large family of 
structurally related mitogens [448] and is a major regulator of normal and abnormal 
angiogenesis associated with tumor growth [449]. The physiological effects of VEGF are 
mediated through binding to two homologous transmembrane tyrosine kinase receptors, 
VEGF receptor-1 and -2 that are expressed on vascular endothelial cells and undergo 
dimerization upon ligand binding [450]. Dimerization triggers signal transduction by 
promoting the phosphorylation of the receptors, and thus, is activating the downstream 
signaling. 
VEGF induces angiogenesis directly by mitogenic effect on endothelial cells [451]. In vitro 
assays showed that VEGF induced endothelial cell invasion into the matrix, where they formed 
capillary-like tubules. VEGF elicits also non-mitogenic responses on vascular endothelial cells. 
By inducing anti-apoptotic signals, VEGF is required not only for proliferation but also for the 
survival of endothelial cells, thus being important for the viability of immature vasculature 
[452]. Additionally, VEGF can increase vascular permeability, leading to leakage of plasma 
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proteins and development of an extravascular matrix, further enhancing the remodeling of 
the environment, favorable for endothelial cell growth [450]. 
Experimental evidence supports the association of increased VEGF expression to the 
activation of several oncogenes like K-ras, H-ras, v-src, HER2, EGFR, FOS or to the loss of tumor 
suppressor p53 [453]. Also, an increased expression of VEGF has been demonstrated in several 
human cancer types that correlates with invasiveness, vascular density, metastasis, 
recurrence, and prognosis [454]. 
4.3.2 Antiangiogenic molecules 
Thrombospondin-1, the first discovered member of a family of multifunctional extracellular 
matrix (ECM) proteins (TSPs 1-5), is the inhibitory activity described above that was purified 
and shown to be a truncated form of thrombospondin-1 (TSP-1) [455]. TSP-1 is a 450 kDa 
homotrimeric glycoprotein that can be divided into structural domains, each domain having 
multiple receptors or molecules to interact in the cell (Fig. 24) [456].  
Figure 24. Structural and functional domains of TSP-1 (from [456]). 
Each subunit of TSP-1 consists of amino (N)- and carboxy (C)-terminal globular domains, a 
region of homology with procollagen and three types of repeated sequence motifs 
designated types 1-3 repeats (Fig. 24). The varied functions of TSP1 are determined by the 
interactions between its structural domains and multiple cell surface molecules [456]. The 
sequence similarities between TSP-1 and TSP-2 suggests that they bind to same molecules 
on the cell surface and thus, functions mediated by these receptors may be common to both 
proteins [457].  
TSP-1 has been shown to regulate very diverse and even opposite cellular processes: 
TSP-1 can be a promoter of the migration for vascular smooth muscle cells, but it is, on the 
other hand, an effective inhibitor of endothelial cell migration [458, 459]. By binding to 
matrix proteins such as fibronectin and collagen and by modulating the activity of 
extracellular proteinases such as matrix metalloproteinases (MMPs) and plasmin, TSP-1 can 
be considered as one of the key players in modulation of the tumor microenvironment [460]. 
It is still controversial, what is the exact biological function of TSP-1 in tumorigenesis and 
angiogenesis, as some studies have found it to contribute to cell transformation [458, 461] 
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and promote neovascularization [462]. TSP-1 downregulation, instead, has been found in 
several primary tumors [458] and in cells transformed in vitro by Ras [463], v-Src [464], v-Myc 
[465], ODC [466], and c-Jun [467]. In a present view TSP-1 is recognized as an endogenous 
inhibitor of angiogenesis and as TSP-2 has equivalent domain structure, it is also shown to be 
a potent inhibitor of angiogenesis [457]. 
5. Matrix modulation for angiogenesis and invasion
During angiogenesis extracellular matrix (ECM) needs to be degraded and modulated for 
endothelial cell migration taking place [396, 468]. Also, conversion to an invasive phenotype 
involves similar events of remodeling, including the attachment of the tumor cells to the 
basement membrane via cell surfaces receptors, and the secretion of enzymes that degrade 
the basement membrane and the underlying stroma [468-470]. Matrix metalloproteinases 
(MMPs) participate by their protein degrading ability in the matrix disruption, tumor 
neovascularization, and metastasis, whereas tissue inhibitors of metalloproteinases (TIMPs) 
downregulate the activity of MMPs, reviewed in [471, 472]. 
5.1 Matrix metalloproteinases (MMPs) 
MMPs belong to a large family of endopeptidases that can cleave any component of ECM 
[471]. Several different MMPs has been characterized in mammals that are divided in soluble 
(e.g. MMP-2 and MMP-9) and membrane-type MMPs (MT-MMPs) and classified further in 
subfamilies based on their structure [471]. Mammalian MMPs share a conserved domain 
structure that consists of a catalytic domain and an autoinhibitory pro-domain (Fig 25). The 
pro-domain contains a conserved cysteine residue that in turn coordinates the zinc ion at the 
active site to inhibit catalysis. MMP-2 and MMP-9 have also fibronectin type II repeats that 
bind to collagens inserted into the catalytic domain (Fig. 25). MMPs are synthetized as latent 
proenzymes and are activated mainly outside the cell by other activated MMPs or serine 
proteases [473]. MMP-2 instead, is activated at the cell surface through a unique multistep 
pathway involving MT1-MMP and TIMP-2 [474]. Removal of an amino-terminal pro-domain is 
required for the production of active (62 and 59 kDa) enzyme forms from the 72 kDa-sized 
inactive proenzyme form [475]. 
Figure 25. Schematic structure of MMPs. MMP2 and MMP9 share a conserved domain structure (adapted from 
[476]). 
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The role of MMPs in tumor angiogenesis and cancer progression is strongly supported by the 
fact that the expression and activity of MMPs have been found increased in almost every type 
of cancer, correlating with advanced tumor stage, increased invasion and metastasis, and 
shortened survival [471]. Specifically, MMP-2 and MMP-9 have been implicated in 
angiogenesis regulation [472, 477, 478]. 
5.2 Tissue inhibitors of metalloproteinases (TIMPs) 
The synthesis, secretion and activation of the MMPs together with the synthesis and secretion 
of their inhibitors, TIMPs, are key regulatory steps in the remodeling of ECM in both normal 
and pathological processes, like angiogenesis and tumor invasion [479]. Four mammalian 
TIMPs (TIMP-1-4) have been identified. They are two-domain molecules, of which the N-
terminal domain performs the MMP-inhibitory function [480] by binding to MMPs. TIMPs 
have various biological activities including the modulation of cell proliferation, cell migration 
and invasion, anti-angiogenesis, and anti- and pro-apoptosis [479]. These activities may 
partially arise from metalloproteinase inhibition, but many of them have been shown to be 
independent of MMP inhibition [479, 481]. The emerging explanation for these contrasting 
roles is that TIMPs function seems to depend on the context so that the tissue 
microenvironment determines finally the mechanism of action. 
5.3 Tenascins 
Tenascin-C (TN-C) is a hexameric, multimodular protein (Fig. 26) that belongs to a highly 
conserved family of large glycoproteins found in the extracellular matrix [482, 483].  
Figure 26. Schematic representation of tenascin-C (adapted from [483]). An amino-terminal oligomerization 
region is followed by consecutively arranged domains of heptad repeats, EGF-like and fibronectin type III repeats, 
and a fibrinogen globe. Alternative splicing and protein modifications are rich sources for numerous TN-C forms.  
The multimodular structure (Fig. 26) enables the tenascins to interact with a high number of 
highly diverse ligands leading to complex cell interactions. TN-C is the best known for its 
function as an adhesion-modulating extracellular matrix protein through binding to 
fibronectin, but TN-C has been shown to have also important and even opposite effects, 
depending on the context, on cell proliferation, migration, angiogenesis, survival, 
transformation, metastasis and immunosurveillance [484]. The normal TN-C expression in 
healthy organism is sparse [485, 486], but it can be rapidly induced in response to pathological 
stress, like upon infection and inflammation [487], and in human cancers [484, 488]. 
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AIMS OF THE STUDY 
The aim of this work was to engineer rodent fibroblasts to overexpress polyamine biosynthetic 
enzymes ornithine and S-adenosylmethionine decarboxylases in sense and antisense 
orientations at constant high levels and to study the effects of their activity on cell growth and 
morphology, and their potential tumorigenicity in immunocompromised mice. 
Further, once these enzymes were found to be transforming, we wanted to compare signal 
transduction pathways in ODC-, AdoMetDC, c-Ha-rasVal12 - and v-src-oncogene transformed 
cells, and search for potential points of convergence that could be common in various 
oncogenic transformation models. 
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MATERIALS AND METHODS 
The methods used in the study are summarized in Table 2 and detailed description of the 
methods can be found in the corresponding original publications. Cell lines and vectors, and 
exact references to them are described in Table 3. Table 4 lists the antibodies used in all four 
publications.  
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 Table 2. Methods 
Method Used in 
Cloning I, III, IV 
Expression vectors Table 3 
Cells and transfections 
Cell lines Table 3 
Stable transfections I, III, IV 
Transient transfections III, IV 
Culturing cells I, II, III, IV 
Cell growth and tumorigenicity assays 
Cell proliferation in high and low serum I, IV 
Soft-agar growth I, III, IV 
Tumorigenicity / nude mice III, IV 
Analysis of biomolecules 
DNA analyses 
Southern blot I 
RNA analyses  
Northern blot I, II, III 
Slot blot I 
Microarrays 
cDNA microarray IV 
Oligonucleotide microarray IV 
RT-PCR IV 
Polyamine analysis I, III 
Analysis of proteins 
Western blotting I, II, III, IV 
Antibodies Table 4 
Cell lysates I, II, III, IV 
Nuclear fractions II, III 
Protein assay I, II, III, IV 
Immunoprecipitation II, III 
Receptor binding assay II 
Enzymatic assays 
ODC activity I, III 
AdoMetDC activity III 
MAPK activity II, III 
JNK activity II, III 
Src kinase activity II 
Histochemistry 
Hematoxylin & eosin staining IV 
Actin filament staining III 
CD31 staining IV 
Laminin staining IV 
Tenascin staining IV 
Functional assays 
Matrigel invasion IV 
Endothelial cell migration IV 
Conditioned media IV 
Gelatin zymography IV 
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Table 3. Cell lines and vectors 




cell line / 
insert 
Used in 
NIH3T3 Mouse fibroblasts - - ATCC CRL-1658 I, II, III, IV 
N1 NIH3T3 pSV2neo ATCC 37149 - [135] I, II, IV 
E2 NIH3T3 pEJ6.6 [489] c-Ha-rasVal12 [135] II 
E4 NIH3T3 pEJ6.6 [489] c-Ha-rasVal12 [135] I, II, IV 




[490] I, II 




























tumors in nude 
mice 




[466] II, IV 
RSVLA29 Rat-1 Rat-1 - - tsLA29src [492] I, II 
R2 - - ts339src of RSV-B77 [493] I 
Rat-1 Rat fibroblasts - - - ATCC CRL-2210 II, III 
Rat-1 neo control Rat-1 pLTRpoly, pSV2neo 
ATCC 77109, 
ATCC 37149 - - III 




insert from pSAMh1 
sense 
[120] III 




insert from pSAMh1 
antisense 
[120] III 
4N NIH3T3 pLTRpoly, pSV2neo 
ATCC 77109, 
ATCC 37149 - - III, IV 




insert from pSAMh1 
sense 
[120] III, IV 




insert from pSAMh1 
antisense 
[120] III 
pcDNA3 4N pcDNA3, pBabe-puro 
Invitrogen, 
[494] - III 
DN SEK1 4N pcDNA3, pBabe-puro 
Invitrogen, 
[494] SEK1(AL) [495] III 
DN JNK1 4N pcDNA3, pBabe-puro 
Invitrogen, 
[494] FLAG-JNK1(APF) [496] III 
pcDNA3 AMDC-S pcDNA3, pBabe-puro 
Invitrogen, 
[494] - - III 
DN SEK1 AMDC-S pcDNA3, pBabe-puro 
Invitrogen, 
[494] SEK1(AL) [495] III 
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DN JNK1 AMDC-S pcDNA3, pBabe-puro 
Invitrogen, 
[494] FLAG-JNK1(APF) [496] III 
pCMV 4N pCMV, pZeoSV2 Invitrogen - - III 
TAM67 4N pCMV, pZeoSV2 Invitrogen TAM67 [497] III 
pCMV AMDC-S pCMV, pZeoSV2 Invitrogen - - III 
TAM67 AMDC-S pCMV, pZeoSV2 Invitrogen TAM67 [497] III 
4N + vector 4N pBabe-puro [494] - - IV 
4N + TSP-1 4N pBabe-puro [494] mouse TSP-1 insert from pJDM [498] IV 
Amdc-s + vector AMDC-S pBabe-puro [494] - - IV 





- - - - IV 
MDA-MB231 Human breast cancer cell line - - - - IV 
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Table 4. Antibodies 
Target Clone or Cat. # Source Method * Publication 
P-Tyrosine pAb - [499] WB I 
PDGFR-a pAb R7 C-H Heldin & L Claesson-Welsh WB II 
PDGFR-b pAb R3 C-H Heldin & L Claesson-Welsh WB II 
p91 pAb c JE Darnell Jr. WB, IP II 
P-Tyrosine mAb 4G10 Upstate Biotechnology Inc. WB, IP II 
Nck mAb 05-160 Upstate Biotechnology Inc. WB II 
PLCg-1 mAb 05-163 Upstate Biotechnology Inc. WB II 
GAP pAb 06-157 Upstate Biotechnology Inc. WB II 
SHC pAb 06-203 Upstate Biotechnology Inc. WB II 
Sos-1 pAb 07-337 Upstate Biotechnology Inc. WB II 
SHPTP2/SYP pAb 06-118 Upstate Biotechnology Inc. WB II 
MAP kinase R2 pAb Erk1-CT Upstate Biotechnology Inc. WB II 
JAK1 whole antisera 06-272 Upstate Biotechnology Inc. WB II 
JAK2 whole antisera 06-255 Upstate Biotechnology Inc. WB II 
PI3K whole antisera p85 Upstate Biotechnology Inc. WB II 
P-Tyrosine mAb PT-66 Sigma WB II 
Erk1/Erk2 mAb Z033 Zymed Laboratories WB II, III 
v-Src mAb 327 Oncogene Science IP II 
Raf-1 pAb C-12 Santa Cruz Biotechnology WB II 
c-Jun/AP-1 pAb N Santa Cruz Biotechnology WB II 
JNK1 pAb C17 Santa Cruz Biotechnology IP II 
JNK1 pAb FL Santa Cruz Biotechnology WB III 
P-c-Jun pAb Ser73 New England Biolabs Inc WB III 
MKK4/JNKK1/SEK1 pAb M-0422 Sigma-Aldrich WB III 
c-Jun/AP-1 pAb Ab-1 Calbiochem-Novabiochem WB III 
CD31 mAb MEC 13.3 BD Pharmingen IHC IV 
Laminin pAb L9393 Sigma-Aldrich IHC IV 
TN-C mAb Mtn15 [500] WB IV 
VEGF pAb 147 Santa Cruz Biotechnology WB IV 
MMP-2 pAb AB808 Chemicon International WB IV 
TSP-1 (Ab4) mAb Ab6.1 NeoMarkers WB IV 
MTI-MMP mAb 113-5B7 Calbiochem-Novabiochem WB IV 
* WB=Western blotting, IP=immunoprecipitation, IHC=immunohistochemistry 
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RESULTS & DISCUSSION 
1. ODC activity is critical for cell transformation
1.1 ODC gene cloned into three different expression vectors in sense and antisense 
orientations  
To be able to study the role of ODC in cell transformation, the human ODC cDNA (an 1.8 kb 
EcoRI-insert of the plasmid pODC10/2H [490]) was cloned in sense and antisense orientations 
into three different expression vector constructs (pHbAPr1neo [491], pLTRpoly [501] and 
pMAMneo (Clontech)). The construct in sense orientation was expected to express ODC over 
the natural, transient and tightly regulated levels at constant and high level, enabling 
observations on its effect on cell morphology. The construct in antisense orientation was 
foreseen to pair with its own endogenous ODC RNA and thus, to prevent it from being 
translated into a functional protein.  
1.2 Stable transfections in NIH3T3 and R2 cells 
NIH3T3 mouse fibroblasts were transfected with pHbApr1neo-S (sense orientation designated 
pAPr(S) cells) or pHb-Apr-1-neo-AS (antisense orientation pAPr(AS) cells) constructs and 
compared to those transfected with pLTRpoly-S or -AS constructs (pLTR(S) and pLTR(AS) cells, 
respectively) and pMAMneo-S and -AS constructs (pMAM(S) and pMAM(AS) cells, 
respectively). pAPr(S) and pLTR(S) cells were growing more rapidly than the non-transfected 
cells and the growth rate of pAPr(AS) and pLTRpoly(AS) cells was reduced in comparison to 
their normal counterparts. To avoid problems caused by clonal variation, uncloned cell pools 
were used to produce the data presented.  
Rous sarcoma virus-infected rat fibroblast R2 cells carrying a temperature inducible src-gene 
mutant were also transfected with both antisense constructs, pHb-Apr-1-neo-AS and 
pLTRpoly-AS.  
1.3 Confirmation of genomic integration and expression of human ODC by DNA and RNA 
analyses, and ODC-activity assays 
The integration of ODC gene into the genome of NIH3T3 cells was confirmed by Southern 
blotting. The analyses showed that the pAPr(S) and pAPr(AS) cells had ODC-construct 
integrated in a lower copy number and with different integration sites than in the 
pLTRpoly/ODC constructs containing cells (data not shown). However, in Northern and slot 
blot assays the pAPr-ODC mRNA species were readily seen (I: Fig 3c and d). The size of the 
chimeric ODC mRNA extracted from the pHbApr1neo/ODC-transfected cells was 2.3 kb, as 
predicted (1.8 kb ODC insert size + 500 bp from the vector) and indistinguishable from the size 
of the endogenous mouse mRNA. Other mRNAs were detected in the cells expressing the 
antisense construct under the b-actin promoter (I: Fig 3c). The larger mRNA is speculated to 
result from unsplicing of the intervening sequences and the smaller is probably a result of 
alternative splicing or rearranged RNA. Notably, the antisense sequence of ODC cDNA 
contains a polyadenylation signal after 145 nucleotides, which results in such short RNAs (£0.2 
kb) difficult to capture by EtOH precipitation and poorly retained in the filter membrane. This 
resulted in very faint signals in Northern blotting. The slot-blot assay in which the membrane 
55 
immobilized RNA is hybridized with a single-stranded oligonucleotide probe, specific to this 
short sequence, circumvented the problem. Both the ODC antisense constructs in pLTRpoly 
and pHb-Apr-1-neo gave rise to this short RNA sequence (I: Fig 3d). The three different 
expression plasmids containing the ODC gene proved to have promoters of different strength. 
ODC activity measurements showed the activity in pAPr(S) cells to be 40-50% of that in pLTR(S) 
cells, where the ODC activity was elevated 50- to 100-fold over the control NIH3T3 cells, grown 
both in the absence or presence of serum (I: Fig. 3e and data not shown). The ODC activity in 
pAPr(AS) and pLTR(AS) cells, in turn, was decreased to almost undetectable levels (I: Fig. 3e).  
1.4 Morphologic transformation 
Transfection of NIH3T3 cells with a pLTRpoly/ODC in sense orientation elicited a complete 
morphological transformation. The cells had acquired an ability to grow over each other’s 
without contact inhibition that is typical for transformed cells. Both in monolayer cultures and 
in soft agar, pLTR(S) cells formed multiple foci (I: Fig. 1b,e). Their normal counterparts or the 
pLTRpoly/ODC in antisense orientation expressing cells retained their epithelioid morphology, 
remained single cells and formed no foci in soft agar (I: Fig. 1a,d and c,f respectively). 
pHbApr1neo vector expressing ODC gene in sense orientation proved to be less potent 
inducer of transformation. This construct transformed cells with a lower efficiency than the 
pLTRpoly construct, however, they grew similarly in a criss-cross fashion and were able to 
induce several foci, but to a lesser extent than the pLTRpoly(S)-cells. pAPr(AS)-cells were 
totally flat and also did not show any signs of transformation. 
1.5 ODC antisense constructs inhibit the v-src -induced transformation 
When the R2 cells are grown in the restrictive temperature of +39.5°C the src-mutant is 
inactive but becomes activated after downshifting to the permissive temperature of +35°C. 
The cell morphology changed correspondingly from normal flat (I: Fig. 4d1) to transformed (I: 
Fig. 4d2). However, when the R2 cells carrying the ODC-antisense construct were grown in 
permissive temperature the cells did not change their morphology, but remained 
untransformed instead (I: Fig. 4d3). This result together with that of ODC activity blocked by 
specific inhibitor DFMO in Rat-1 LA29 cells (also carrying temperature sensitive RSV mutant) 
preventing transformation (I: Fig. 4a1-3) led us to suggest that ODC might transduce the 
transforming activity of Src.  
1.6 ODC in other transformation models and human cancers 
Soon after the publication of (I) Moshier et al. reported similar results, supporting the idea of 
ODC having a role in cell transformation [502]. Also, ODC induction has subsequently been 
reported in various rodent cell systems to be critical for neoplastic transformation [65] or to 
have transforming potential in combination with other oncogenes, like Ras, v-Src and Myc [15, 
136, 137, 489]. Importantly, several transgenic mouse models have further demonstrated that 
ODC activity is sufficient for tumor promotion [503-506], even though systems that fail in 
transformation have been reported too [507]. Also, the functional role of ODC in prostate 
tumorigenesis has been linked to malignant transformation of prostatic epithelium first time 
not only in vitro models, but also in vivo mouse experiments and patient samples by Shukla-
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Dave et al [508]. In addition, various oncogenic stimuli and genetic alterations in ODC have 
been shown to cause ODC dysregulation, as outlined in Table 5. 
Table 5. ODC is dysregulated by a variety of oncogenic stimuli and genetic alterations in the ODC gene 
Stimuli Reported action Reference 
Oncogenic Ras ODC expression and activity dramatically induced [15, 137, 489] 
c-Myc ODC gene is a transcriptional target of c-Myc [63, 136, 140] 
TPA  Increased ODC translation leads to ODC hyperactivity in response to transformation [509] 
Overexpression of translation 
initiation factor eIF4E 
Increased translation initiation of ODC leads to induction 
of ODC activity  [65, 510] 
Genetic alteration 
Alternative splicing of ODC mRNA  ODC protein truncated and stabilized in human hepatocellular carcinoma [511] 
ODC 3ʹ-UTR (bases 1851-2151) ODC mRNA stability in carcinomas is dependent of the activity of mTORC1 [100, 101] 
Point mutation in ODC gene  ODC expression is increased in response to Myc [512] 
SNP in the 1st intron of ODC gene High ODC activity is a mediator of tumor promotion [52, 96] 
ODC1 +316 SNP A genetic marker for colon cancer risk and prognosis [513, 514] 
2. Signaling in ODC-, c-Ha-ras -oncogene and v-src-transformed cells and transformation-
specific convergence points
The proliferation of normal cells is tightly regulated by the growth factors in the cellular 
environment. In contrast, the escape of transformed cells from this control of growth factors 
is a hallmark of cancer [281]. Supposing that a transformed cell should display constitutive or 
inappropriate activation of one or more components in the signaling pathway to gain 
independence from the upstream growth factors and, asking if transformations induced by 
different oncogenes would converge to a shared intermediate, we decided to search for 
common signaling events in various transformation models. By comparing c-Ha-rasVal12 and v-
src transformed cells to ODC-induced cell transformation using the well-characterized PDGF-
signaling in normal cells as a reference, we wanted to elucidate these signaling events.  
Even though the PDGF-signaling events have been relatively well documented in cells 
transformed by HRAS -oncogene (the most commonly activated oncogene in human cancers), 
several conflicting results had remained in the literature [515-518]. Similarly, regarding v-src, 
the first and most studied oncogene, discrepant results have been reported of the PDGF-
induced signaling in v-src transformation [518, 519]. The ODC-induced signaling events were 
almost fully uncharacterized. Notably, ODC may be a central player in the signaling of many 
oncoproteins, as its activity is constitutively elevated in many cells transformed by different 
chemical carcinogens [30] and oncogenes, like v-src, neu and ras [13, 15, 17, 135]. Further, it 
has been shown to be a transcriptional target of c-myc and c-fos oncogenes [63, 520], and v-
src-induced transformation can be blocked by transcription of ODC antisense RNA or by ODC-
specific inhibitor (I) [521], making it a very interesting model to study. 
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2.1 c-Ha-rasVal12- and ODC-transformed cells show reduced protein tyrosine phosphorylation 
in response to PDGF stimulation 
Our analysis of the phosphorylation status of several signaling molecules, like PLCg-1, GAP, 
Nck, Syp or Shc, previously indicated to have transforming activity or to be constitutively 
activated in different cancer cells showed that none of these molecules are, however, 
characteristic of cells transformed by c-Ha-rasVal12 or ODC (II: Fig. 2).  
Activation and phosphorylation of MAPKs (Erk1/Erk2) by their upstream kinases upon growth 
factor stimulation plays a key role in the activation of several transcription factors [522]. 
Constitutively active MEK1 (kinase upstream of MAPKs) is also shown to be able to transform 
NIH3T3 cells [523] and MAPKs themselves have been found to be activated in cells 
transformed by several oncogenes, like ras, src, raf and mos [220, 523-525]. To our surprise, 
no constitutive upregulation of Erk1 or Erk2 was found in ras-, ODC- or v-src-transformed cells, 
assessed by electrophoretic mobility shift in Western blot or activity increase in kinase assay 
(II: Fig. 4). The mobility shift and increase in kinase activity were readily seen upon PDGF 
stimulation of normal cells. We conclude that the MAPK (Erk1/Erk2) pathway is not 
responsible for the propagation of the proliferative signals and maintenance of the 
transformation by the ODC-, ras- and v-src-oncogenes in these cell lines. 
2.2 Sos-1 and Raf-1 exhibit a constitutively retarded electrophoretic mobility in all three 
transformed cells lines 
Translocation and concomitant phosphorylation of Sos-1 from the cytoplasm to the receptor 
complex on the plasma membrane have been shown to be required for Ras activation and cell 
transformation [526]. Sos-1 converts inactive GDP-bound Ras to active GTP-Ras, which in turn 
is able to interact and activate serine-theronine kinase Raf-1[527, 528]. Activated Raf-1 shows 
a reduced mobility in agarose gel [528]. In line with these earlier results and similarly seen in 
PDGF-stimulated normal NIH3T3, or Rat-1 LA29 cells grown in non-permissive conditions, ras-
, ODC- or v-src-transformed cells presented constitutive and retarded migration of Sos-1 and 
Raf-1 (II: Fig. 3). Interestingly, we did not find the MAPK activity to correlate with the 
phosphorylation state of Sos-1 or Raf-1 in ras-, ODC- or v-src-transformed cells and therefore, 
the phosphorylating kinase is suggested to be a different from Erk1 and Erk2.  
2.3. Downregulation of the PDGF a- and b-receptors in NIH3T3 cells transformed by ras and 
ODC, and v-src induced transformation of rat fibroblasts causes a preferential decrease of 
PDGF b-receptor 
Previous results have shown that many oncogenes can modulate the function of growth factor 
receptors and induce autocrine loops [277]. Cells transformed by ras, for example, have been 
found to become refractory to PDGF stimulation and display loss or suppression of some of 
the downstream effectors [515, 518, 519] or expression of some growth regulatory genes [15, 
516, 529]. Both normal level of PDGF receptors [518, 529, 530] and of suppressed receptor 
autophosphorylation [530] that would interfere with the binding of signaling molecules to the 
receptor have been reported. 
We found a marked reduction in PDGF a- and b-receptors in ras- and ODC-transformed cells 
in comparison to the normal cells, shown by both protein and mRNA levels and by receptor 
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binding assay (II: Fig. 6). Since this was in contrast with the previously published data in ras-
transformed cells, we considered the possibility that the opposite results could be derived 
from different oncogene expression levels. Indeed, the comparison of the two ras-
transformed cell lines E2 and E4 showed the decrease of receptor levels being much stronger 
in E4 cells, expressing much higher ras-levels than E2 cells. Similarly, the difference in 
oncogene expression levels was also seen in phosphorylation of PLCg and GAP proteins, 
previously reported with discrepant results (II: Fig. 7). Also, PDGF b-receptor level in Rat-1 LA-
29 cells following v-src induction, was profoundly decreased correlating with the degree of 
morphological transformation. We conclude that the oncogene expression levels determine 
the degree of aberration in signaling and may explain previous conflicting results. 
2.4 The ras-, ODC- and v-src-transformed cells display a constitutive increase in 
phosphorylation of c-Jun on serines 63 and 73 
To follow our idea of finding a constitutively active signaling mediator, we analyzed nuclear 
fractions of ras-, ODC- and v-src-transformed cells by Western blotting. Previously, c-Ha-ras-
induced c-Jun phosphorylation on its transactivation domain has been detected by 32P-
orthophosphate labeling [345, 531]. In line with these results, we detected a constitutive 
increase in phosphorylation of c-Jun on serines 63 and 73 in all three transformation models, 
using phospho-specific antibodies to c-Jun (II: Fig. 8a,b).  
Since we had already excluded the MAP kinases (Erk1/Erk2) and the JAK-STAT pathway (II: Fig. 
5) as potential kinases constitutively active in ras-, ODC- and v-src-transformed cells, the
possible activation of c-Jun kinases (JNKs) was examined. The JNK1 and JNK2 are thought to
be the principal kinases responsible for c-Jun phosphorylation on its transactivation domain
on serines 63 and 73 [344, 345]. Our results in ODC-transformed cells show that JNK1 activity
is highly elevated in these cells (II: 8c) and is in line with the previous results that show an
elevated JNK activation in cells transiently transformed with the ras- or v-src-oncogenes [496,
532]. Intriguingly, we did not find a correlation between JNK-activity both in immunocomplex
or solid phase kinase assays, and c-Jun phosphorylation on serine 73 in ras- and v-src-
transformed cells (II: Fig. 8c and data not shown, respectively). This suggests that there is still
an unknown kinase that is different from JNK1-3 [533], capable of phosphorylating the
activation domain of c-Jun in these ras- and v-src-transformed cells.
3. Overexpression or block of S-AdoMetDC induces cell transformation in murine
fibroblasts
It has been shown in numerous studies that polyamines are associated with cell 
transformation and cancer development. This together with our previous results that showed 
ODC to have oncogenic potential when overexpressed (I), prompted us to test if AdoMetDC 
could have a similar role in cell transformation as well.  
3.1 AdoMetDC induces tumorigenic transformation in sense and antisense orientations 
We cloned a 1.65kb insert of human AdoMetDC cDNA in sense and antisense orientations in 
pLTRpoly vector, known to induce high level of expression of inserted genes (I). Two types of 
rodent fibroblast cell lines were stably transfected with these constructs together with a neo-
selection marker (pSV2neo), mouse NIH3T3 and Rat-1cells. Rat-1 cells have been used in many 
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in vitro transformation studies due to their low incidence of focus formation and poor growth 
in soft agar [534]. The empty pLTRpoly vector together with a neo-selection marker (pSV2neo) 
were also transfected into the parental cells, providing controls accordingly (4N for NIH3T3 
and Rat-1-neo for Rat-1). 
The overexpression of AdoMetDC in sense orientation in NIH3T3 cells (Amdc-s) resulted in a 
complete morphological transformation, with elongated morphology, in a growth without 
contact inhibition, with formation of multiple foci in tissue culture, with disintegrated actin 
filaments and in an acquired ability to grow in soft agar (III: Fig.1 Ab,e,h). Very surprisingly, the 
same morphological and growth features were detected in AdoMetDC antisense construct-
expressing cells (Amdc-as). To note, culturing Amdc-as cells in the presence of low 
spermidine concentration (1 µM) was vital to prevent the counterselection of high Amdc-as 
expressors, as the expression of the AdoMetDC antisense construct blocks the synthesis of 
spermidine and cell proliferation. However, Amdc-as+spd cells had a little less elongated 
morphology (III: Fig.1 Ac), but a similar degree of actin filament disintegration (III: Fig.1 Af) 
and growth in soft agar (III: Fig.1 Ai). Similar induction of transformation was seen in Rat-1 
Amdc-s and Rat-1 Amdc-as +spd cells (III: Fig.1 Bb,c). The parental control cells from 
both cell lines showed similar epithelioid and stringent density-dependent morphology (III: 
Fig.1 Aa for NIH3T3, Ba for Rat-1). Also, 4N cells presented normal actin filaments and were 
not able to grow in soft agar (III: Fig.1 Ad,g).  
Northern blotting showed the mRNA expression of AdoMetDC cDNA in NIH3T3 transfectants 
(III: Fig.2A). Amdc-s cells had an average of 30-40-fold higher constitutive activity than the 
control cells, with spd-addition having only a marginal effect (III: Fig.2 B. The high AdoMetDC 
activity seemed to correlate with the degree of morphological transformation, but ODC-
activity remained on the level comparable to control, spd-addition having no marked effect 
either. Thus, we could not find any signs of feed-back control by polyamines of their 
biosynthetic enzymes that is reported earlier [8, 20], at least at this low level of spermidine.   
The Amdc-as cells had, as expected, very low levels of AdoMetDC-activity (III: Fig.2 B left), but 
interestingly, showed about a 12-fold increase in ODC-activity (III: Fig.2 B right), when cultured 
with spermidine. We assume this to be a compensatory mechanism, related to the role of 
AdoMetDC as a rate-limiting enzyme for the higher and vital polyamines. By keeping up the 
ODC activity and thus putrescine production, these cells have better a change to survive. The 
polyamine content of Amdc-as+spd cells (III: Fig.2 C) was similar to the one in ODC 
overproducing cells [466]. As a difference, the increase in putrescine was not that high than 
in ODC-transformed cells, but instead, more putrescine was further converted to spermidine. 
In Amdc-s cells the polyamine content was very different in comparison to normal or Amdc-
as cells, with almost no putrescine, and the balance being almost solely on the end product, 
spermine (III: Fig.2 C).  
The higher putrescine levels in Amdc-as+spd cells are in line with earlier reports connecting 
the increase in putrescine to cell proliferation and transformation [466, 504, 535]. However, 
when we consider the situation in AdoMetDC-induced transformation, where putrescine 
levels were lower than in normal control cells and the overall polyamine balance was clearly 
towards the end product spermine, the unconditional importance of putrescine in 
dysregulated growth could be questioned. Also reflecting the opposite patterns of total 
polyamines in AdoMetDC- or ODC-induced transformation [466] (Fig 27) encourages us to 
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suggest that it is rather the imbalanced ratio of polyamines than just a single polyamine 
change, which leads to cell transformation. 
 
 
         
Figure 27. Polyamine levels in AdoMetDC-S and -AS cells (left) (III: Fig2 C) and in ODC-transformed cells (right). 
On the left black bars = putrescine, gray bars = spermidine, striped bars = spermine for AdoMetDC and on the 
right white bars = puterscine, dark grey bars = spermidine, black bars = spermine for ODC. Adapted from III and 
[466].  
 
For the tumorigenicity assays all four cell lines (4N, Amdc-s, Amdc-as and Amdc-as+spd) were 
injected into the flanks of athymic mice. Only the transformed cell lines were able to induce 
tumors, but with different potency. Strikingly, the Amdc-s cells were able to induce 
aggressively growing, highly invasive tumors penetrating rapidly through the muscle and fat 
tissues into the peritoneal cavity. In a similar assay, the ODC-transformed cells were able to 
induce large and well-vascularized tumors, but only at the site of inoculation [466]. 
 
Of note, Zabala-Letona et al [536] have recently demonstrated a crucial role of dysregulated 
AdoMetDC activity also in prostate cancer tumorigenesis and validated the same mechanism 
both in mouse models and in human cancer specimens. These results further support our 
findings that AdoMetDC has an important function in controlling cell phenotype and 
tumorigenesis. 
 
3.2 AdoMetDC-induced transformation converges on constitutive phosphorylation of 
endogenous c-Jun at Ser73 
 
Numerous reports have documented the necessity of Erk1/Erk2 MAPK cascade activation in 
cellular growth [537] and in several oncogene-induced transformation models MAPK pathway 
is activated [538, 539]. However, we did not detect constitutive activation of Erk1 and Erk2 in 
the AdoMetDC-transformed cells, neither by electrophoretic mobility shift in Western blot (III: 
Fig.3B), nor by in kinase assay (III: Fig.3B). This indicates that the activation of Erk1/Erk2 cannot 
be responsible for the maintenance of AdoMetDC-induced transformation and therefore is in 
line with our results with c-Ha-ras-, v-src-, and ODC-transformed cells (II) and the results of 
others in other models [540]. 
 
Exclusion of constantly activated Erk1/Erk2 signaling pathway as a possible mechanism of 
AdoMetDC-induced transformation led us to consider other pathways known to be connected 
to oncogenesis. The parallel pathway of JNK kinases has been shown to be involved not only 
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in stress-induced signaling, but also in cell cycle control, cell proliferation and transformed 
growth [343]. The performed kinase assays showed that the endogenous JNK was 
constitutively activated in NIH3T3 and Rat-1 cells transformed by AdoMetDC overexpression 
and this activation resulted in the phosphorylation of c-Jun at serine 73 (III: Fig. 4A, B). That 
the increase in JNK activity was not just a resultant of transformation was excluded by 
transient transfection of AdoMetDC cDNA into NIH3T3 cells, which showed activation of JNK 
as well. Interestingly, Amdc-as+spd cells displayed an increase in c-Jun phosphorylation, 
despite of absent JNK activation (III: Fig. 4B, left). This conundrum is discussed below (see 3.3). 
 
3.3 Dominant-negative mutants of JNK pathway reverse the transformed morphology of 
AdoMetDC-overexpressing cells 
 
Previous studies indicating the importance of c-Jun and its activating phosphorylation in Ras-
transformation [365, 541, 542] together with our results displaying constitutive increase in c-
Jun phosphorylation on Ser63 and Ser73 in ras-, v-src- and ODC-transformed cells (II) 
stimulated us to investigate the effects of dominant-negative mutants of this pathway in 
AdoMetDC-induced transformation. Dominant-negative mutants of SEK-1 (immediate 
upstream activator of JNKs), JNK-1 and TAM-67 (lacking the transactivation domain of c-Jun) 
were transfected into the 4N and Amdc-s cells. This led to a reversion towards the normal, 
epithelioid morphology in Amdc-s cells, with an accumulation of multinucleated cells, 
probably due to the dysregulated cytokinesis (III: Fig. 5A). Expression of TAM67 resulted in the 
most efficient reversion of the transformed phenotype and into inhibition of soft agar growth 
(III: Fig. 5Af,g, Ca,b) that was also seen in Amdc-as+spd cells (III: Fig. 5B, Cc,d), in which the 
DN-SEK1 or DN-JNK1 appeared not to be effective. This might be a consequence of Amdc-
as+spd cells showing JNK-independent phosphorylation of c-Jun (III: Fig. 4A left, B left) that 
could, indeed, be a result of activation of another kinase, different from JNK or Erk1/Erk2. A 
similar situation, a JNK- and Erk-independent and transformation-specific phosphorylation, 
has been reported for FosB [543]. 
 
Our finding in relation to the constitutive phosphorylation of c-Jun on Ser73 on its 
transactivation domain in Amdc-s and Amds-as+spd cells and their dominant negative c-Jun 
(TAM67)-induced morphological reversion towards epithelioid phenotype argues for the 
importance of transactivation domain of c-Jun in AdoMetDC-induced transformation. To our 
knowledge this data is the first to indicate that the polyamine biosynthetic enzymes, and 
thereby polyamines known to be essential for growth, may require the c-Jun transcription 
factor for eliciting their cellular responses. This is also the first example of a protein whose 
overexpression or the block of synthesis can lead to transformation. This data emphasizes the 
fact how strictly the AdoMetDC levels have to be regulated, in order not to disturb its delicate 
balance.  
 
4. AdoMetDC-induced aggressively growing invasive tumors present chaotic 
neovascularization 
 
The aggressive growth of AdoMetDC-induced tumors in nude mice (III) was remarkable. We 
were fascinated to study the potential molecular mechanisms behind this haphazard growth 
model that seemed to result in disorganized angiogenesis, leading to abnormal tumor 
vasculature and exceptionally high invasive capability.  
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4.1 Invasive growth in vitro and in vivo 
 
Amdc-s, ODC-overexpressing (Odc-n), Ras-transformed (Ras E4), human fibrosarcoma (HT-
1080), breast carcinoma (MDA-MB-231) and NIH3T3 control cells were cultured in a 
reconstituted matrix of basement membrane components (3D-Matrigel) and their invasive 
capacity were compared without any support of other stromal cells. This assay showed that 
the Amdc-s cells had extensively branched growth pattern, being thus by far the most 
invasively growing cell line of all cell lines tested (IV: Fig. 2).  
 
This extreme invasive capacity of Amdc-s cells was further manifested by the in vivo assay, 
where they were injected into athymic mice. This induced aggressively and invasively growing 
tumors (IV: Fig. 1) able to penetrate through the layer of fat, fascia, muscles, and parietal 
peritoneum and, in uttermost short time, to fill the peritoneal cavity with tumor mass and 
reach the tissue parenchyma of small intestine, pancreas, liver and spleen. This is a prominent 
difference from the situation we have seen earlier for ODC overexpressing cells in nude mice, 
in which the transformed cells gave rise to rapidly growing, large and well-vascularized 
fibrosarcomas at the site of inoculation [466] or other oncogenes (as ras or v-src) with local 
invasive properties [544, 545]. 
 
4.2 AdoMetDC-transformed cells induce mosaic vasculature with irregular or missing CD31-
staining for endothelium  
 
The immunohistochemical analysis of the tumors induced in Amdc-s injected nude mice 
revealed widely varied patterns of endothelial cell marker CD31-staining. Within the same 
tumor section, we detected mainly vessels that were highly irregular in shape and size, 
together with some almost regular tube structures. CD31 immunoreactivity showed either 
clear gaps or lacked completely (IV: Fig. 3 Aa and Ab). Not only the endothelium, but also 
basement membrane structures depicted by laminin staining, seemed to be aberrant in Amdc-
s cells. The deposition of laminin varied from nearly complete to punctuate, or was totally 
missing (IV: Fig. 3 Ba and Bb). Overall, it seemed that the tumor cells were directly exposed to 
the lumen of these vessel-like structures. In difference to tumor tissue, the blood vessels in 
the normal skin tissues on the very same tumor slides, presented complete and homogenously 
stained layer of CD31-positive endothelial cells and strong staining for laminin (IV: Fig. 3 Ac 
and Ac).  
 
From these results it was clear that the chaotic neovascularization with irregular formed and 
sized vessels induced by Amds-s cells was not a result of typical endothelial sprouting, vascular 
splitting or co-option types of angiogenesis. Instead, two other mechanisms, vasculogenic 
mimicry [546] or mosaicism [439, 441], were considered as possibilities. Folberg and Maniotis 
[425] defined vasculogenic mimicry as tumor cells’ ability to form fluid-conducting channels 
rich in laminin and later proposed them to rather dampen than to promote invasive and 
metastatic phenotype of melanomas [547]. As the vessel-like structures in the tumors induced 
by Amdc-s cells were lined by tumor cells, but stained not positive for laminin, vasculogenic 
mimicry was not considered as responsible mechanism for this phenotype.  
 
The lack of CD31-staining, combined with an apparent tumor cell lining of Amdc-s induced 
tumor vessel-like structures could be an example of mosaicism, even though di Tomaso et al 
show only focal (and not completely lacking) regions within tumor cells [441]. Our tumor 
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vessel-like structures lined with tumor cells, but without CD31 positive staining display also 
mosaic regions, where the CD31-positive staining showed gaps of discontinuity. However, it 
cannot be concluded that mosaicism would be a sole mechanism to induce angiogenesis in 
our model.  
 
Interestingly, the publishing of reports describing tumor cells in the vessels of various tumors 
has continued. So far, tumor cells contributing to the vessel-like structures have been found 
at least in colon carcinoma [439], neuroblastoma [440] and in glioblastomas [422, 423]. The 
concept of vasculogenic mimicry has also persisted the initial heavy skepticism towards the 
idea of microcirculatory channels lined externally by tumor cells, and several cancers with 
vessel structures resembling vasculogenic mimicry have been reported, e.g. prostate [428], 
breast [548], gastric [549] and ovarian cancers [550]. The idea of simultaneous or consequent 
action of possible angiogenic mechanisms was also rehashed recently by a report showing the 
co-existence of mosaic and mimicry structures in human gastric adenocarcinoma [551].  
 
4.3 Secretion of chemotactic molecules 
 
To test if the Amdc-s cells were able to secrete factors that would stimulate endothelial cell 
migration, conditioned media (CM) was collected from normal 4N and Amdc-s cells. Their 
potency to stimulate the migration of bovine endothelial cells in 3D-collagen gel together with 
CM from control cell lines, the ODC-transformed cells and purified basic fibroblast growth 
factor as positive and phosphate buffered saline as a negative control was performed. Amdc-
s cells were found to secrete even more potent angiogenic factors than the ODC-transformed 
cells (IV: Fig. 4A), previously found to induce highly vascularized tumors [466].  
 
4.4 Angiogenic switch 
 
4.4.1 VEGF is upregulated in Amdc-s cells 
 
We were interested to see what role VEGF would play in AdoMetDC-induced transformation, 
as VEGF is known to be a major regulator of abnormal angiogenesis associated with tumor 
growth [449]. Indeed, Amdc-s cells were found to secrete VEGF in clearly increased amounts 
(IV: Fig. 4C). By itself, VEGF has been shown to promote only leaky and unstable vessels with 
fragmented membranes and cooperation with other factors seems to be needed for the 
maturation of blood vessels [447]. As the levels of secreted VEGF were rather moderate in 
Amdc-s cells, AdoMetDC-induced angiogenesis is likely to need other pro- and/or anti-
angiogenic factors as well. Interestingly, our DNA microarray profilings of the Amdc-s cells and 
their normal counterparts, revealed up-regulation of several angiogenic proteins, like 
angiopoietin-like 2 [552] and proliferin [553], possibly contributing to Amdc-s-tumor 
angiogenesis.  
 
4.4.2 TSP-1 is downregulated in Amdc-s cells and its reintroduction reverses the 
transformed phenotype and inhibits invasion 
 
As the angiogenic switch is a balance between pro-angiogenic and anti-angiogenic factors, we 
performed genome-wide DNA microarray analyses to find out, weather other factors than 
VEGF might be involved in the Amdc-s-induced neovascularization. Affymetrix MOE430 Set -
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arrays revealed 20-fold down-regulation of anti-angiogenic factor TSP-1. Also the TSP-1 
protein levels were reduced in Amdc-s cells (IV: Fig 5A) and their CM (IV: S Fig 4). 
 
By reintroduction of TSP-1 into Amdc-s cells using a TSP-1-containing expression vector, we 
wanted to study further the potential role of TSP-1 in AdoMetDC-induced cell proliferation 
and invasive capacity. TSP-1 expression was confirmed by Western blotting (IV: Fig. 5B). The 
restoration of TSP-1 in Amdc-s cells inhibited their proliferation (IV: Fig. 5Ca), which was not 
be due apoptosis (IV: Fig. 5Cb). Importantly, the invasive growth capacity of TSP-1-transfected 
Amdc-s cells was dramatically reduced in 3D-Matrigel-assay (IV: Fig. 5D).  
 
To our surprise, TSP-2 that shares the same structural domains than TSP-1 and is also a potent 
inhibitor of angiogenesis [457], was slightly up-regulated (2.9-fold) in Amdc-s cells. In 
difference to Amdc-s cells, the less aggressive and invasive ODC-transformed cells displayed 
7.9-fold down-regulation of TSP-2 in microarray, which is in line with an earlier report [466]. 
 
In the very aggressive Amdc-s cells TSP-1 was shown to be one of the most down-regulated 
genes. VEGF was up-regulated, but only moderately. By comparing this situation to ODC-
transformation that shows a similar down-regulation of TSP-1, but no change in VEGF levels 
[466], we propose that in fibrosarcomas the switch to an angiogenic phenotype and tumor 
expansion may largely depend on the levels of TSP-1.  
 
4.5 Deregulation of expression of the extracellular matrix proteins 
 
Modulation and degradation of ECM, a multistep process necessary for tumor growth, 
angiogenesis and invasion, involves many players, like metalloproteinases (MMPs) ([471, 472, 
476]. Indeed, genome-wide DNA microarray profiling showed a ~5.3-fold upregulation of 
MMP-2 in AdoMetDC-transformed cells in comparison to their normal counterparts (IV: Fig. 
5A), confirmed also by induction seen in RT-PCR, zymography and as a secreted fully active 
form in CM prepared from Amdc-s cells (IV: Fig 5B,C,D). However, MMP-9 was not found to 
be elevated in either of the microarrays (data not shown), RT-PCR nor in zymography (IV: Fig. 
5B,C) 
 
As tissue inhibitor of metalloproteinase-2 (TIMP-2) has beside its role as a MMP-2 inhibitor 
another function together with MT-MMP1 in the activation of MMP-2 [474], we were 
interested to see its expression as well. Similar to MMP-2, the increased TIMP-2 levels in CM 
were detected in Amdc-s cells compared to normal 4N cells (IV: Fig. 5D). 
  
4.6 Differential expression of tenascin isoforms 
 
Microarray analyses of Amdc cells revealed also elevated levels of a large extracellular matrix 
protein tenascin-C that is known to have versatile roles in connection to angiogenesis, 
malignant transformation and metastasis [484]. The higher-molecular weight isoform of TN-C 
was shown to be increased in CM of Amdc-s, Odc-n and Ras E4 cells, but not in the control 4N 
cells (IV: Fig.8A). Intriguingly, TN-C was also richly expressed in the walls of the Amdc-s-
induced tumor blood vessels and also, in long ECM-strands lining the tumor cells, similarly to 
invasive melanomas [554].  
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As Amdc-s cells showed increased expression of MMP-2 and the large isoform of TN-C, one 
could speculate that while not being the main triggers of angiogenic switch, they have at least 
the potency to create a remodeled matrix that would be conducive to tumor cell invasion and, 















































Polyamines and their biosynthetic enzymes have proved to be indispensable to cells 
throughout the metazoan kingdom. The strict and very unique control systems have 
guaranteed the balance in the levels of different polyamines, as any aberration could be fatal 
to cells. Ornithine decarboxylase (ODC), the first and key enzyme in polyamine biosynthesis, 
has gained a special focus: it is rapidly reacting to exogenous signals like growth factors and 
becomes constitutively active in transformation induced by carcinogens, viruses or 
oncogenes. Our question, whether ODC is just an innocent bystander or even critical for 
cancerous growth, needed to be answered. Here we show by overexpressing ODC at constant 
high levels that it is able to induce full morphological transformation, increase cell 
proliferation and anchorage-independent growth in immortalized rodent fibroblasts. Also, 
blocking of the ODC activity by synthesizing antisense RNA or using a specific inhibitor of ODC, 
reverts the v-src-induced transformation. These results suggest that ODC should be 
recognized as a proto-oncogene, acting at the convergence point in the signaling pathways 
induced by several oncogenes. This makes ODC a potentially good target exploitable in cancer 
therapy. For example, Myc-driven neuroblastomas and lymphomas are conditions, in which 
inhibition of ODC as a Myc target may be effective and bypass the difficulty of direct Myc 
inhibition [140, 555, 556]. Hence, ODC and polyamines continue to be promising targets for 
anticancer therapy design [3, 7].  
By analyzing the PDGF-induced signal transduction pathway in v-src, c-Ha-rasVal12 a n d  
ODC-transformed cells we were able to answer our second question about possible 
common denominators in transformation. The fact that the signaling in all three 
types of transformation models indeed culminated in phosphorylation of c-Jun 
Ser73 in its transactivation domain, was very interesting. As the complexity of the 
signaling pathways has increased and the pathways intersect at multiple points, it has 
become increasingly difficult to ascribe distinct biological functions with a precision. 
Already the fact that the phosphorylating kinase responsible for c-Jun activation is 
not the same in these three transformation models, describes the difficulty of the effort 
well.  
The results of AdoMetDC-overexpression in sense and antisense orientations in 
rodent fibroblasts were intriguing. To our knowledge, this is the first time, when an 
overproduction or a block of an activity of a single enzyme is transforming. Also, the 
AdoMetDC-transformed cells showed a c-Jun phosphorylation on Ser73 and the 
introduction of DN c-Jun mutant TAM67 reverted the transformed phenotype and 
abolished the anchorage-independent growth. It is tempting to speculate that the 
phosphorylation of c-Jun or specific AP-1 components would be an important point of 
convergence in the transforming action of AdoMetDC and many other oncogenes.  
We show also that AdoMetDC-transformation induces highly invasive and aggressive tumors 
in mice, characterized by chaotic angiogenesis. The induction of neovasculature or vessel-
like structures that have, instead of endothelial cell layer, luminal areas with cells only from 
the tumor or originating from the tumor but further evolved, has far-reaching consequences 
– it is an open route for metastasis. Many anti-vasculature therapies have been shown 
to be disappointing and resulted later in relapse of the cancer. This could be due to the 
induction of hypoxia in tumors, in which the collapsing and thus non-functional vasculature 
leads to the lack or reduced oxygen in the tissues [557]. If this type of mosaic vessel 
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structures proves to be common for other aggressively growing cancers, it could serve as a 
chemotherapeutical strategy to attack the tumor instead of the vasculature. 
Our results, showing ODC and AdoMetDC overexpression leading to cellular transformation 
have been later confirmed by several other in vitro and in vivo results. It is notable, however, 
that these and our results on common mediators in transformation cannot be directly 
extrapolated to transformation of human cells (in vitro) due to the vast diversity and 
extraordinary complexity of human cancers [191, 558]. 
As a further concern, initially the signaling pathways were described as linear chains, but are 
now known to be far more complex: separate cascades interplay, the same kinases and 
phosphatases function in various pathways simultaneously, more substrates and feedback 
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